{"gene":"ZFP36L1","run_date":"2026-04-28T23:00:24","timeline":{"discoveries":[{"year":2002,"finding":"ZFP36L1 (BRF1) was functionally identified as an essential regulator of AU-rich element (ARE)-dependent mRNA decay. Genetic rescue of a mutant cell line (slowC) deficient in ARE-mRNA degradation by retroviral cDNA library screening identified BRF1 as the causative gene; slowC carried frame-shift mutations in both BRF1 alleles. siRNA knockdown and transfection experiments confirmed that BRF1 accelerates ARE-mRNA decay and that its zinc-finger domains are required for both ARE binding and mRNA destabilization activity.","method":"Retroviral cDNA library functional rescue screen, flow cytometry of GFP-ARE reporter, siRNA knockdown, zinc-finger mutagenesis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods including genetic rescue, mutagenesis of zinc fingers, and siRNA in the same study; independently corroborated","pmids":["12198173"],"is_preprint":false},{"year":2004,"finding":"ZFP36L1 (BRF1) mRNA-destabilizing activity is regulated by protein kinase B (PKB/Akt), which phosphorylates BRF1 at serine 92 (S92). Phosphorylation by PKB impairs BRF1's in vitro ARE-mRNA decay activity without affecting ARE binding, but induces complex formation with the scaffold protein 14-3-3, sequestering BRF1 and stabilizing ARE-containing transcripts.","method":"In vitro mRNA decay assay with recombinant BRF1, in vitro kinase assay, co-immunoprecipitation with 14-3-3, site-directed mutagenesis (S92A)","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — reconstituted in vitro decay assay plus mutagenesis plus 14-3-3 co-IP; multiple orthogonal methods in one study","pmids":["15538381"],"is_preprint":false},{"year":2004,"finding":"ZFP36L1 (TIS11b) binds to AU-rich elements in the 3'-UTR of VEGF mRNA and destabilizes it, reducing VEGF mRNA half-life from ~130 to ~60 min. A 75 bp domain containing two consensus AU-rich motifs was identified as the binding and destabilization target. RNP immunoprecipitation confirmed the interaction in live cells, and siRNA knockdown of TIS11b elevated VEGF mRNA levels in primary adrenocortical cells.","method":"mRNA half-life measurements, RNP immunoprecipitation, deletion mapping of 3'-UTR, siRNA knockdown","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (half-life, RNP-IP, siRNA) with functional validation in primary cells","pmids":["15467755"],"is_preprint":false},{"year":2004,"finding":"ZFP36L1 (BRF1) and TTP each contain two activation domains that recruit mRNA decay enzymes (deadenylases, decapping enzymes, and exonucleases) involved in deadenylation, decapping, and 3'-to-5' and 5'-to-3' exonucleolytic decay. BRF-1's N-terminal activation domain functions as a binding platform for mRNA decay machinery, linking ARE-containing mRNAs to the decay apparatus.","method":"Co-immunoprecipitation of decay enzymes with BRF-1, tethered mRNA decay assays with heterologous RNA-binding domain fusions, dominant-negative overexpression","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP of multiple decay enzymes, functional tethering assays, confirmed with dominant-negative mutants","pmids":["15687258"],"is_preprint":false},{"year":2004,"finding":"siRNA-mediated knockdown of BRF1 (ZFP36L1) stabilized ARE-reporter mRNA and increased fluorescence of a GFP-ARE reporter in HT1080 cells, confirming its endogenous role as an ARE-mRNA destabilizer. Selective knockdown of p40AUF1/p45AUF1 but not BRF1 stabilized GM-CSF mRNA, demonstrating that BRF1 and AUF1 regulate overlapping but distinct ARE-mRNA subsets.","method":"siRNA knockdown, fluorescent ARE-reporter assay, GM-CSF mRNA stability measurement","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 — clean siRNA KD with quantitative reporter readout, but single lab","pmids":["14976220"],"is_preprint":false},{"year":2006,"finding":"BRF1 (ZFP36L1) protein stability and mRNA decay activity are co-regulated by PKB/Akt phosphorylation at two cooperative sites, S92 and S203. Phosphorylation at both sites is required for 14-3-3 binding, BRF1 protein stabilization (preventing proteasomal degradation), and inactivation of ARE-mRNA decay. Alanine mutations at both sites uncoupled BRF1 from PKB regulation, causing constitutive mRNA decay. BRF1 is labile (half-life <3 h) and stabilized by phosphorylation-dependent 14-3-3 binding.","method":"In vitro kinase assay, site-directed mutagenesis (S92A/S203A), proteasome inhibitor experiments, cell fractionation, PKBα knockout cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro kinase assay plus mutagenesis plus genetic (PKBα KO cells), multiple orthogonal approaches","pmids":["17030608"],"is_preprint":false},{"year":2007,"finding":"ZFP36L1 (BRF-1) and TTP deliver ARE-mRNAs to processing bodies (PBs) in human cells. Depletion of endogenous TTP and BRF proteins impaired localization of ARE-reporter mRNAs to PBs. BRF-1 can tether mRNAs to PBs and TTP can nucleate PB formation on untranslated mRNAs. ARE-mRNA PB localization requires the TTP/BRF-1 N- and C-terminal domains and occurs downstream of mRNA polysome release.","method":"siRNA depletion, fluorescent reporter mRNA tracking, dominant-negative overexpression, tethering assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (depletion, tethering, live imaging), replicated across labs","pmids":["17369404"],"is_preprint":false},{"year":2008,"finding":"ZFP36L1 (BRF1) is phosphorylated by MAPK-activated protein kinase 2 (MK2) at four sites including S54, S92, and S203, which inhibits its ARE-mRNA decay activity. This inhibition does not alter BRF1's ability to bind AREs or associate with mRNA decay enzymes, suggesting MK2 targets a step downstream of RNA binding and decay enzyme recruitment.","method":"In vitro kinase assay with BRF1 fragments, co-expression of active MK2, ARE-mRNA decay assays, mutagenesis of phosphorylation sites","journal":"RNA","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay with defined substrates, mutagenesis mapping, functional ARE-decay assay","pmids":["18326031"],"is_preprint":false},{"year":2009,"finding":"ZFP36L1 (TIS11b) regulates steroidogenic acute regulatory protein (StAR) mRNA stability through direct binding to UAUUUAUU AU-rich repeats in the extended 3'-UTR of the 3.5-kb StAR transcript. Cotransfection of TIS11b selectively decreased cytomegalovirus-driven Star mRNA and luciferase-Star 3'-UTR reporters. siRNA knockdown of TIS11b specifically enhanced 3.5-kb Star mRNA induction and halved STAR protein induction, demonstrating coupling of mRNA decay to cholesterol metabolism in steroidogenic cells.","method":"Direct RNA complex formation assay, luciferase-3'UTR reporter assay, siRNA knockdown, ARE mutagenesis, cotransfection","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (RIP, reporter assay with ARE mutations, siRNA) linking ZFP36L1 to specific physiological outcome","pmids":["19179481"],"is_preprint":false},{"year":2009,"finding":"ZFP36L1 (TIS11b/ZFP36L1) expression is regulated by VHL tumor suppressor protein in renal cancer cells. In normoxia, VHL overexpression increased hsa-miR-29b levels, which decreased TIS11B protein by post-transcriptional regulation. In hypoxia, VHL overexpression increased TIS11B mRNA stability and protein levels, which in turn downregulated VEGF mRNA. Silencing TIS11B reversed VHL-mediated VEGF downregulation in hypoxia.","method":"miRNA expression analysis, TIS11B knockdown with siRNA, VEGF mRNA and protein quantification, TIS11B mRNA stability assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 — knockdown with functional readout (VEGF mRNA levels), single lab, multiple methods","pmids":["19801654"],"is_preprint":false},{"year":2010,"finding":"ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by directly binding the 3'-UTR of Stat5b mRNA to trigger its degradation, thereby reducing STAT5B protein levels. ZFP36L1 overexpression dramatically decreased erythroid colony formation in human hematopoietic progenitors, and this effect was confirmed by Stat5b siRNA knockdown. Co-overexpression of ZFP36L1 and ZFP36 had a cumulative effect on Stat5b downregulation.","method":"3'-UTR RNA binding assay, overexpression in CD34+ cells, erythroid colony assay, siRNA knockdown of Stat5b, co-overexpression experiments","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2–3 — direct 3'UTR binding plus functional colony assay plus siRNA epistasis, single lab","pmids":["20702587"],"is_preprint":false},{"year":2010,"finding":"Cell-penetrating fusion proteins of ZFP36L1 (R9-ZFP36L1, TAT-ZFP36L1) were efficiently internalized into living cells and decreased endogenous VEGF mRNA half-life and VEGF protein levels. Intratumoral injection of R9-ZFP36L1 in Lewis Lung Carcinoma mouse models significantly reduced tumor growth and decreased expression of multiple angiogenic and inflammatory cytokines (VEGF, FGF-a, TNFα, IL-1α, IL-6), with concomitant reduction in tumor vascularization.","method":"Protein transduction domain fusion constructs, in vitro mRNA decay assays, intratumoral injection in mouse tumor model, cytokine quantification","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — functional in vitro and in vivo experiments with exogenous ZFP36L1 protein, single lab","pmids":["20802528"],"is_preprint":false},{"year":2010,"finding":"ZFP36L1 (ZFP36L1) is induced by growth factors and cytokines in keratinocytes (EGF, FGF, serum, etc.) and by scratch wounding. siRNA-mediated knockdown of ZFP36L1 in HaCaT keratinocytes prolonged elevated VEGF mRNA levels following EGF stimulation, consistent with ZFP36L1 destabilizing VEGF mRNA in the wound healing context.","method":"siRNA knockdown, VEGF mRNA quantification, scratch wound assay","journal":"Growth factors","confidence":"Low","confidence_rationale":"Tier 3 — siRNA knockdown with mRNA readout, single method, single lab","pmids":["20166898"],"is_preprint":false},{"year":2014,"finding":"ZFP36L1 (Brf1) operates downstream of FGF/ERK MAP kinase signaling in mouse embryonic stem cells (mESCs) to regulate pluripotency by destabilizing target mRNAs including Nanog. FGF/ERK signaling upregulates Brf1, which disrupts core pluripotency gene expression and attenuates mESC self-renewal. Brf1 overexpression preferentially regulates mesendoderm commitment during differentiation, accelerating primitive streak marker expression.","method":"Conditional Brf1 overexpression in mESCs, mRNA stability assays (Nanog half-life), ERK pathway manipulation, differentiation assays with lineage markers","journal":"Proceedings of the National Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 — direct mRNA stability measurements, genetic overexpression, epistasis with ERK pathway, single lab","pmids":["24733888"],"is_preprint":false},{"year":2014,"finding":"ZFP36L1 and ZFP36L2 bind to the 3'-UTR of LDLR mRNA and recruit the CCR4-NOT deadenylase complex, destabilizing LDLR mRNA. The C-terminal regions of ZFP36L1 and ZFP36L2 are directly phosphorylated by p90 ribosomal S6 kinase (RSK, downstream of ERK), causing dissociation of the CCR4-NOT complex and stabilization of LDLR mRNA. Antisense oligonucleotides targeting the ZFP36L1/L2 binding sites on LDLR mRNA upregulated LDLR mRNA and protein.","method":"Proteomic identification of 3'-UTR binding proteins (pull-down MS), CCR4-NOT co-immunoprecipitation, in vitro phosphorylation by RSK, antisense oligonucleotide experiments","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 — proteomic identification plus co-IP of CCR4-NOT complex plus in vitro kinase assay, multiple orthogonal methods","pmids":["25106868"],"is_preprint":false},{"year":2014,"finding":"ZFP36L1 (ZFP36L1) binds the BCL2 3'-UTR AU-rich element and mediates BCL2 mRNA degradation in malignant B cells. RNA electrophoretic mobility shift assay (REMSA) showed direct ZFP36L1-BCL2 ARE interaction. ZFP36L1 knockdown in BCL1, ACHN, and Ramos cells increased BCL2 mRNA levels. Luciferase reporter assays showed wild-type but not zinc-finger mutant ZFP36L1 downregulated BCL2 ARE-containing constructs; deletion of the ARE core abrogated this effect.","method":"RNA EMSA, siRNA/shRNA knockdown in multiple cell lines, 3'UTR luciferase reporter assay, zinc-finger domain mutagenesis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — EMSA plus reporter assay with mutagenesis plus knockdown in multiple cell types, single lab","pmids":["25014217"],"is_preprint":false},{"year":2015,"finding":"In LPS-stimulated RAW264.7 macrophages, ZFP36L1 protein is hyperphosphorylated, which promotes complex formation with 14-3-3 adapter protein and decreases interaction with the CCR4-NOT deadenylase subunit Caf1a. Knockdown of Zfp36l1 increased basal Mkp-1 mRNA levels by prolonging its half-life, and this elevated MKP-1 inhibited p38 MAPK activation during LPS stimulation, consequently downregulating TNFα and TTP expression.","method":"siRNA knockdown, mRNA half-life assay, co-immunoprecipitation (14-3-3 and Caf1a), phosphorylation analysis","journal":"Journal of inflammation","confidence":"Medium","confidence_rationale":"Tier 2–3 — siRNA knockdown with mRNA half-life, co-IP of 14-3-3 and Caf1a interactions, single lab","pmids":["26180518"],"is_preprint":false},{"year":2016,"finding":"ZFP36L1 and ZFP36L2 are critical for maintaining quiescence in developing B lymphocytes before pre-BCR expression and for reestablishing quiescence after pre-BCR-induced expansion. These proteins suppress a posttranscriptional regulon of mRNAs whose protein products cooperatively promote S-phase entry, thus promoting VDJ recombination and selection of cells expressing immunoglobulin-μ at the pre-BCR checkpoint.","method":"Conditional knockout mice (Zfp36l1/l2 double KO in B cells), RNA-seq, BrdU incorporation cell-cycle analysis, V(D)J recombination assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — conditional double KO in vivo with defined molecular phenotype (cell cycle regulon), replicated across multiple functional assays","pmids":["27102483"],"is_preprint":false},{"year":2017,"finding":"ZFP36L1 is an FXR target gene that post-transcriptionally regulates bile acid metabolism by destabilizing Cyp7a1 mRNA. Gain-of-function and loss-of-function of ZFP36L1 reciprocally regulated Cyp7a1 mRNA and bile acid levels in vivo. Mice with hepatic ZFP36L1 deletion were protected from diet-induced obesity and hepatosteatosis due to impaired lipid absorption linked to altered bile acid metabolism.","method":"Conditional hepatic Zfp36l1 KO mice, adeno-associated virus overexpression, Cyp7a1 mRNA half-life assay, bile acid quantification, diet-induced obesity model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic gain- and loss-of-function with defined molecular (Cyp7a1 mRNA) and physiological (bile acids, obesity) phenotypes","pmids":["28891815"],"is_preprint":false},{"year":2018,"finding":"ZFP36L1 and ZFP36L2 inhibit cell proliferation and arrest the cell cycle at G1 phase in a cyclin D-dependent and p53-independent manner. Forced expression of ZFP36L1 inhibited cyclin D expression and cell proliferation in p53-null and p53-mutant colorectal cancer cell lines. Zinc-finger domain mutation abolished these antiproliferative effects, confirming that RNA-binding activity through the tandem zinc-finger domain is required.","method":"Inducible overexpression, siRNA knockdown, cell cycle analysis (flow cytometry), cyclin D mRNA/protein measurements, zinc-finger domain mutagenesis in three cell lines including p53 KO","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2–3 — overexpression and KD with mutagenesis in multiple cell lines, single lab","pmids":["29426877"],"is_preprint":false},{"year":2019,"finding":"ZFP36L1 directly regulates OA pathogenesis in chondrocytes by destabilizing mRNAs of two HSP70 family members (HSPA1A and related members). ZFP36L1 is specifically upregulated in OA chondrocytes. Genetic ablation or silencing of Zfp36l1 abrogated experimental OA in mice, and this was associated with increased HSP70 expression. Overexpression of HSPA1A in joint tissue protected against OA by inhibiting chondrocyte apoptosis.","method":"Adenovirus-mediated overexpression/knockdown, genetic KO mouse OA model (intraarticular injection), identification of HSP70 as direct mRNA targets, HSPA1A overexpression rescue experiment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic KO and OE models plus identification of direct mRNA targets plus rescue experiment","pmids":["30622281"],"is_preprint":false},{"year":2019,"finding":"ZFP36L1 functions as a tumor suppressor by binding to ARE sequences in the 3'-UTRs of HIF1A, CCND1, and E2F1 mRNAs for degradation, suppressing hypoxic signaling and cell-cycle progression. Wild-type but not zinc-finger-mutant ZFP36L1 bound HIF1A 3'-UTR in dual luciferase reporter assays and RNA-EMSA, mediating HIF1A mRNA degradation. Systematic RNA pull-down with WT vs. mutant ZFP36L1 and whole-transcriptome sequencing identified 1,410 potential direct targets.","method":"RNA pull-down with WT vs. zinc-finger mutant ZFP36L1, transcriptome sequencing, dual luciferase reporter assay, RNA-EMSA, forced expression and silencing in bladder cancer cells in vitro and in vivo","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — systematic RNA pull-down plus EMSA plus reporter assay with mutagenesis, functional in vivo xenograft validation","pmids":["31551365"],"is_preprint":false},{"year":2020,"finding":"miR-93-3p promotes keratinocyte proliferation and migration during skin wound healing by directly targeting ZFP36L1, reducing its expression. ZFP36L1 silencing mirrored miR-93-3p overexpression effects on proliferation and migration. ZFP36L1 in turn targets ZFX mRNA for degradation; ZFX overexpression promoted proliferation and migration, placing ZFP36L1 upstream of ZFX in keratinocyte wound-healing signaling.","method":"In vivo mouse wound model, miRNA overexpression/inhibition, siRNA knockdown, luciferase 3'UTR reporter assay for miR-93-3p→ZFP36L1 and ZFP36L1→ZFX interactions","journal":"Molecular therapy. Nucleic acids","confidence":"Medium","confidence_rationale":"Tier 2–3 — in vivo model plus reporter validation of two regulatory steps, single lab","pmids":["33473330"],"is_preprint":false},{"year":2021,"finding":"ZFP36L1 facilitates antibody-secreting cell (ASC) homing to the bone marrow by directly regulating the mRNA abundance of G protein-coupled receptor kinase 2 (GRK2) and the integrin chains α4 and β1. Loss of ZFP36L1 caused ASC accumulation in spleen and liver with reduced bone marrow homing. Differential effects on early vs. late ASCs correlated with the expression of CXCR4 and integrins α4/β1 regulated by ZFP36L1.","method":"Zfp36l1 conditional KO mice, flow cytometry of ASC localization, identification of GRK2/integrin α4/β1 as direct ZFP36L1 mRNA targets, CXCR4 expression analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — conditional KO in vivo with mechanistic identification of direct mRNA targets linking migration phenotype to molecular mechanism","pmids":["33306108"],"is_preprint":false},{"year":2022,"finding":"ZFP36L1 controls small cell lung cancer (SCLC) neuroendocrine plasticity by binding and destabilizing SOX2 and INSM1 mRNAs, two transcription factors required for SCLC neuroendocrine differentiation. LSD1 binds and represses ZFP36L1; upon LSD1 inhibition, ZFP36L1 expression is restored, blocking the neuroendocrine phenotype and inducing a non-neuroendocrine inflammatory phenotype. ZFP36L1 was identified as required for LSD1 inhibitor sensitivity in a genome-wide CRISPR/Cas9 screen.","method":"Genome-wide CRISPR/Cas9 loss-of-function screen, ZFP36L1 forced expression, RNA-IP demonstrating ZFP36L1 binding to SOX2/INSM1 mRNAs, mRNA stability assays, LSD1 ChIP","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — genome-wide CRISPR screen plus direct RNA binding (RIP) plus mRNA stability plus ChIP for upstream regulator, multiple orthogonal methods","pmids":["36008402"],"is_preprint":false},{"year":1996,"finding":"The cMG1 gene (later identified as ZFP36L1) is a primary response gene induced 2- to 6-fold by mitogens including EGF, angiotensin II, serum, and insulin in a rat intestinal epithelial cell line. Cyclic AMP-elevating agents blocked EGF-induced cMG1 mRNA increase, and depletion of protein kinase C blocked AII- but not EGF-induced increases, indicating that both PKC-dependent and PKC-independent signaling pathways stimulate ZFP36L1 expression.","method":"Northern blot mRNA quantification, PKC depletion, cAMP signaling inhibition, differential mitogen stimulation","journal":"FEBS letters","confidence":"Low","confidence_rationale":"Tier 3 — mRNA expression measurements only, no mechanistic protein-level functional data","pmids":["1628738"],"is_preprint":false},{"year":1996,"finding":"Berg36 (ZFP36L1) immediate early gene expression is induced by calcium ionophore in Ramos human B cells, and antisense blockade of Berg36 expression partially inhibited ionophore-induced apoptosis, implicating ZFP36L1 as a requirement for apoptosis induced through calcium signaling in B cells. IL-4 rescue from apoptosis was accompanied by inhibition of Berg36 expression.","method":"Antisense oligonucleotide knockdown, apoptosis assays, IL-4 and calcium ionophore treatment of Ramos B cells","journal":"European journal of immunology","confidence":"Low","confidence_rationale":"Tier 3 — antisense KD with apoptosis phenotype, no molecular mechanism identified, single lab","pmids":["8898945"],"is_preprint":false},{"year":2011,"finding":"The TIS11 family members (ZFP36, ZFP36L1/BRF-1, ZFP36L2/BRF-2) bind ARE-containing mRNAs and promote their rapid degradation through multiple mechanisms: they recruit deadenylases (CCR4-NOT, PARN), decapping enzymes (DCP1/2), and exonucleases (XRN1, exosome), and their activity is regulated by phosphorylation (MK2, PKB), protein stability (proteasomal degradation), 14-3-3 binding, and subcellular localization.","method":"Review synthesizing co-IP, in vitro decay, phosphorylation, and localization studies from multiple labs","journal":"Wiley interdisciplinary reviews. RNA","confidence":"Medium","confidence_rationale":"Tier 2–3 — synthesis of replicated findings across multiple labs; mechanistic details independently validated","pmids":["21278925"],"is_preprint":false},{"year":2018,"finding":"ZFP36L1 and ZFP36L2 act redundantly in myogenesis. Mice with conditional double KO of Zfp36l1 and Zfp36l2 in Pax7-expressing satellite cells had reduced body weight, reduced skeletal muscle mass, fewer satellite cells, and impaired muscle regeneration following cardiotoxin injury. Single KO of either gene alone did not produce the muscle phenotype, demonstrating functional redundancy.","method":"Single and double conditional KO mice (Pax7-Cre), immunostaining of muscle sections, cardiotoxin injury regeneration model, satellite cell quantification","journal":"Skeletal muscle","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic double KO with clear muscle phenotype and redundancy demonstrated through single vs. double KO comparison","pmids":["30526691"],"is_preprint":false}],"current_model":"ZFP36L1 is a tandem CCCH zinc-finger RNA-binding protein that binds AU-rich elements (AREs) in the 3'-UTRs of target mRNAs (including VEGF, HIF1A, CCND1, BCL2, Cyp7a1, Nanog, Stat5b, SOX2, INSM1, GRK2, and integrin α4/β1 mRNAs) and promotes their deadenylation and degradation by recruiting the CCR4-NOT deadenylase complex and other mRNA decay enzymes; its destabilizing activity is reversibly inactivated by PKB/Akt- and MK2-mediated phosphorylation at S92 and S203, which induces 14-3-3 binding and sequesters the protein from the decay machinery, while RSK (downstream of ERK) phosphorylation of its C-terminus dissociates the CCR4-NOT complex; through these mechanisms ZFP36L1 controls cell quiescence in lymphocytes, erythroid differentiation, bile acid metabolism, neuroendocrine plasticity, muscle satellite cell maintenance, and antibody-secreting cell homing."},"narrative":{"teleology":[{"year":1996,"claim":"Initial characterization established ZFP36L1 as an immediate-early gene induced by mitogens and calcium signaling, but its molecular function was unknown.","evidence":"Northern blot in mitogen-stimulated epithelial cells and antisense knockdown in B cells showing partial apoptosis inhibition","pmids":["1628738","8898945"],"confidence":"Low","gaps":["No molecular function identified beyond expression induction","Antisense knockdown apoptosis result not independently confirmed","No direct target mRNAs identified"]},{"year":2002,"claim":"A genetic rescue screen established ZFP36L1 as an essential ARE-mRNA decay factor, resolving its molecular function as an RNA-binding protein that accelerates mRNA turnover through its zinc-finger domains.","evidence":"Retroviral cDNA rescue of ARE-decay-deficient slowC cells carrying biallelic ZFP36L1 frameshift mutations, validated by siRNA and zinc-finger mutagenesis","pmids":["12198173"],"confidence":"High","gaps":["Mechanism of decay enzyme recruitment unknown","Identity of endogenous mRNA targets unresolved"]},{"year":2004,"claim":"The mechanism by which ZFP36L1 couples ARE recognition to mRNA destruction was elucidated: it contains activation domains that recruit deadenylases, decapping enzymes, and exonucleases, and its first physiological target—VEGF mRNA—was identified.","evidence":"Co-IP of decay enzymes with ZFP36L1, tethered decay assays, RNP-IP confirming VEGF mRNA binding, and half-life measurements in primary adrenocortical cells","pmids":["15687258","15467755","14976220"],"confidence":"High","gaps":["Structural basis for decay enzyme recruitment unknown","Full repertoire of endogenous targets not defined"]},{"year":2004,"claim":"Discovery that PKB/Akt phosphorylates ZFP36L1 at S92 to inhibit its decay activity without blocking ARE binding revealed the first signaling mechanism controlling this protein, with 14-3-3 sequestration as the inactivation mode.","evidence":"In vitro kinase assay, reconstituted decay assay with phospho-mimetic mutants, co-IP with 14-3-3","pmids":["15538381"],"confidence":"High","gaps":["Contribution of additional phosphosites unknown","In vivo relevance of PKB regulation not tested"]},{"year":2006,"claim":"The phosphoregulation model was refined: cooperative PKB phosphorylation at both S92 and S203 is required for 14-3-3 binding and ZFP36L1 protein stabilization, revealing that ZFP36L1 is a labile protein whose abundance and activity are co-regulated by the same phosphorylation events.","evidence":"Double S92A/S203A mutagenesis, proteasome inhibitor rescue, PKBα knockout cells","pmids":["17030608"],"confidence":"High","gaps":["Ubiquitin ligase responsible for ZFP36L1 degradation not identified","Relationship between protein turnover and functional output in vivo unclear"]},{"year":2007,"claim":"ZFP36L1 was shown to deliver ARE-mRNAs to processing bodies for degradation, establishing its role in subcellular compartmentalization of mRNA decay.","evidence":"siRNA depletion, fluorescent mRNA tracking, and tethering assays in human cells","pmids":["17369404"],"confidence":"High","gaps":["Whether P-body localization is required for or merely accompanies decay not resolved","Relative contribution of cytoplasmic vs. P-body decay unclear"]},{"year":2008,"claim":"MK2 was identified as a second kinase inactivating ZFP36L1 at overlapping sites (S54, S92, S203), acting downstream of p38 MAPK stress signaling and inhibiting decay at a step beyond RNA binding and enzyme recruitment.","evidence":"In vitro kinase assays with ZFP36L1 fragments, active MK2 co-expression, ARE-decay functional assays","pmids":["18326031"],"confidence":"High","gaps":["Exact post-recruitment step blocked by MK2 phosphorylation unknown","Relative physiological importance of MK2 vs. PKB phosphorylation undefined"]},{"year":2014,"claim":"The CCR4-NOT deadenylase complex was identified as the specific effector recruited by ZFP36L1's C-terminus, and RSK (downstream of ERK) was shown to phosphorylate this region to dissociate CCR4-NOT and stabilize target mRNAs such as LDLR, completing the picture of three kinase inputs converging on ZFP36L1.","evidence":"Proteomic 3′-UTR pull-down, CCR4-NOT co-IP, in vitro RSK phosphorylation, antisense oligonucleotide validation","pmids":["25106868"],"confidence":"High","gaps":["Structural basis of CCR4-NOT interaction and its phosphorylation-dependent dissociation not resolved","Relative contribution of deadenylation vs. other decay routes for individual targets unknown"]},{"year":2014,"claim":"ZFP36L1's target repertoire was expanded to include Nanog mRNA in embryonic stem cells, positioning it as an effector of FGF/ERK signaling that attenuates pluripotency and biases mesendoderm differentiation.","evidence":"Conditional overexpression in mESCs, Nanog mRNA half-life measurement, ERK pathway epistasis","pmids":["24733888"],"confidence":"Medium","gaps":["Full ZFP36L1 target set in ESCs not defined","In vivo embryonic phenotype of Zfp36l1 loss not reported in this context"]},{"year":2016,"claim":"Conditional double knockout of Zfp36l1 and Zfp36l2 in B cells revealed that these proteins enforce quiescence during lymphocyte development by suppressing a post-transcriptional regulon of cell-cycle-promoting mRNAs, establishing a physiological role in adaptive immunity.","evidence":"Conditional double KO mice, RNA-seq, BrdU cell-cycle analysis, V(D)J recombination assays","pmids":["27102483"],"confidence":"High","gaps":["Individual contributions of ZFP36L1 vs. ZFP36L2 to the quiescence regulon not separated","Identity of critical individual target mRNAs within the regulon not fully resolved"]},{"year":2017,"claim":"ZFP36L1 was established as a metabolic regulator downstream of FXR: it destabilizes Cyp7a1 mRNA to control bile acid synthesis, and hepatic deletion protects against diet-induced obesity, linking mRNA decay to systemic metabolic homeostasis.","evidence":"Conditional hepatic Zfp36l1 KO, AAV overexpression, Cyp7a1 mRNA half-life, bile acid quantification, diet-induced obesity model","pmids":["28891815"],"confidence":"High","gaps":["Whether additional hepatic ZFP36L1 targets contribute to the metabolic phenotype not defined","Human relevance of the Cyp7a1-bile acid axis regulation by ZFP36L1 not tested"]},{"year":2018,"claim":"Functional redundancy between ZFP36L1 and ZFP36L2 was demonstrated in muscle satellite cells, where double but not single knockout caused satellite cell depletion and impaired regeneration, extending the quiescence-enforcement paradigm beyond lymphocytes to stem cell biology.","evidence":"Single and double conditional KO in Pax7+ satellite cells, cardiotoxin injury regeneration model","pmids":["30526691"],"confidence":"High","gaps":["Direct mRNA targets in satellite cells not identified","Mechanism of satellite cell loss (exhaustion vs. differentiation vs. death) not resolved"]},{"year":2019,"claim":"ZFP36L1's tumor-suppressor function was mechanistically defined through identification of HIF1A, CCND1, and E2F1 as direct targets, linking ARE-mediated decay to suppression of hypoxic signaling and cell-cycle progression, while systematic RNA pull-down identified over 1,400 potential target mRNAs.","evidence":"RNA pull-down with WT vs. zinc-finger mutant ZFP36L1, transcriptome-wide sequencing, RNA-EMSA, reporter assays, in vivo xenograft","pmids":["31551365"],"confidence":"High","gaps":["Fraction of 1,410 candidate targets that are functionally relevant unknown","Whether tumor-suppressor activity is context-dependent across cancer types not established"]},{"year":2021,"claim":"ZFP36L1 was found to direct antibody-secreting cell trafficking to bone marrow by regulating GRK2 and integrin α4/β1 mRNA levels, revealing a role in immune cell migration distinct from its quiescence function.","evidence":"Conditional KO mice, flow cytometry of ASC distribution, identification of GRK2 and integrin mRNAs as direct targets","pmids":["33306108"],"confidence":"High","gaps":["Whether ZFP36L1 controls homing of other immune cell types unknown","Mechanism discriminating which targets are regulated in ASCs vs. other cell types unclear"]},{"year":2022,"claim":"ZFP36L1 was identified as a master regulator of neuroendocrine plasticity in SCLC: it destabilizes SOX2 and INSM1 mRNAs, and its epigenetic silencing by LSD1 is required for maintenance of the neuroendocrine phenotype, explaining LSD1 inhibitor sensitivity.","evidence":"Genome-wide CRISPR screen, RNA-IP for SOX2/INSM1, mRNA stability assays, LSD1 ChIP","pmids":["36008402"],"confidence":"High","gaps":["Whether ZFP36L1 controls neuroendocrine plasticity in other tumor types unknown","Full set of ZFP36L1 targets mediating phenotypic switching not defined"]},{"year":null,"claim":"The structural basis for ZFP36L1's selective recruitment of the CCR4-NOT complex and how phosphorylation at distinct sites differentially modulates deadenylase association, P-body delivery, and proteasomal turnover remains unresolved; the rules governing target selectivity among the >1,400 candidate ARE-mRNAs in different cell types are also undefined.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal or cryo-EM structure of ZFP36L1 in complex with CCR4-NOT or ARE RNA","Target selectivity rules across cell types not defined","In vivo contribution of individual phosphorylation sites (S54, S92, S203) not dissected by knock-in"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0,2,3,14,15,21,24]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,3,14,27]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[17,19]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[0,3,6,14,27]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,5,7,14]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[17,23]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[17,19]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[10,13,28]}],"complexes":[],"partners":["CNOT1","YWHAB","DCP1A","XRN1","PARN"],"other_free_text":[]},"mechanistic_narrative":"ZFP36L1 is a tandem CCCH zinc-finger RNA-binding protein that recognizes AU-rich elements (AREs) in the 3′-UTRs of target mRNAs and promotes their deadenylation and degradation by recruiting the CCR4-NOT deadenylase complex, decapping enzymes, and exonucleases, thereby delivering ARE-containing transcripts to processing bodies [PMID:12198173, PMID:15687258, PMID:25106868, PMID:17369404]. Its mRNA-destabilizing activity is reversibly inactivated by PKB/Akt phosphorylation at S92 and S203, which induces 14-3-3 binding and protects ZFP36L1 from proteasomal degradation, and by MK2 phosphorylation, while RSK-mediated phosphorylation dissociates the CCR4-NOT complex to stabilize target mRNAs [PMID:17030608, PMID:18326031, PMID:25106868]. Through post-transcriptional control of functionally diverse ARE-containing mRNAs—including VEGF, HIF1A, CCND1, Nanog, Cyp7a1, SOX2, INSM1, Stat5b, GRK2, and BCL2—ZFP36L1 regulates lymphocyte quiescence, erythroid differentiation, bile acid metabolism, neuroendocrine cell plasticity, satellite cell maintenance, and antibody-secreting cell homing [PMID:27102483, PMID:20702587, PMID:28891815, PMID:36008402, PMID:30526691, PMID:33306108]. Conditional knockout studies demonstrate that ZFP36L1 acts redundantly with ZFP36L2 in B-cell quiescence and muscle satellite cell biology, while uniquely controlling hepatic Cyp7a1 mRNA turnover to regulate bile acid homeostasis and protect against diet-induced obesity [PMID:27102483, PMID:30526691, PMID:28891815]."},"prefetch_data":{"uniprot":{"accession":"Q07352","full_name":"mRNA decay activator protein ZFP36L1","aliases":["Butyrate response factor 1","EGF-response factor 1","ERF-1","TPA-induced sequence 11b","Zinc finger protein 36, C3H1 type-like 1","ZFP36-like 1"],"length_aa":338,"mass_kda":36.3,"function":"Zinc-finger RNA-binding protein that destabilizes several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis (PubMed:12198173, PubMed:15467755, PubMed:15538381, PubMed:17030608, PubMed:19179481, PubMed:20702587, PubMed:24700863, PubMed:25014217, PubMed:25106868, PubMed:26542173). Acts as a 3'-untranslated region (UTR) ARE mRNA-binding adapter protein to communicate signaling events to the mRNA decay machinery (PubMed:15687258). Functions by recruiting the CCR4-NOT deadenylase complex and components of the cytoplasmic RNA decay machinery to the bound ARE-containing mRNAs, and hence promotes ARE-mediated mRNA deadenylation and decay processes (PubMed:15687258, PubMed:18326031, PubMed:25106868). Also induces the degradation of ARE-containing mRNAs even in absence of poly(A) tail (By similarity). Binds to 3'-UTR ARE of numerous mRNAs (PubMed:12198173, PubMed:15467755, PubMed:15538381, PubMed:17030608, PubMed:19179481, PubMed:20702587, PubMed:24700863, PubMed:25014217, PubMed:25106868, PubMed:26542173). Positively regulates early adipogenesis by promoting ARE-mediated mRNA decay of immediate early genes (IEGs) (By similarity). Promotes ARE-mediated mRNA decay of mineralocorticoid receptor NR3C2 mRNA in response to hypertonic stress (PubMed:24700863). Negatively regulates hematopoietic/erythroid cell differentiation by promoting ARE-mediated mRNA decay of the transcription factor STAT5B mRNA (PubMed:20702587). Positively regulates monocyte/macrophage cell differentiation by promoting ARE-mediated mRNA decay of the cyclin-dependent kinase CDK6 mRNA (PubMed:26542173). Promotes degradation of ARE-containing pluripotency-associated mRNAs in embryonic stem cells (ESCs), such as NANOG, through a fibroblast growth factor (FGF)-induced MAPK-dependent signaling pathway, and hence attenuates ESC self-renewal and positively regulates mesendoderm differentiation (By similarity). May play a role in mediating pro-apoptotic effects in malignant B-cells by promoting ARE-mediated mRNA decay of BCL2 mRNA (PubMed:25014217). In association with ZFP36L2 maintains quiescence on developing B lymphocytes by promoting ARE-mediated decay of several mRNAs encoding cell cycle regulators that help B cells progress through the cell cycle, and hence ensuring accurate variable-diversity-joining (VDJ) recombination and functional immune cell formation (By similarity). Together with ZFP36L2 is also necessary for thymocyte development and prevention of T-cell acute lymphoblastic leukemia (T-ALL) transformation by promoting ARE-mediated mRNA decay of the oncogenic transcription factor NOTCH1 mRNA (By similarity). Participates in the delivery of target ARE-mRNAs to processing bodies (PBs) (PubMed:17369404). In addition to its cytosolic mRNA-decay function, plays a role in the regulation of nuclear mRNA 3'-end processing; modulates mRNA 3'-end maturation efficiency of the DLL4 mRNA through binding with an ARE embedded in a weak noncanonical polyadenylation (poly(A)) signal in endothelial cells (PubMed:21832157). Also involved in the regulation of stress granule (SG) and P-body (PB) formation and fusion (PubMed:15967811). Plays a role in vasculogenesis and endocardial development (By similarity). Plays a role in the regulation of keratinocyte proliferation, differentiation and apoptosis (PubMed:27182009). Plays a role in myoblast cell differentiation (By similarity)","subcellular_location":"Nucleus; Cytoplasm; Cytoplasmic granule; Cytoplasm, P-body","url":"https://www.uniprot.org/uniprotkb/Q07352/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZFP36L1","classification":"Not Classified","n_dependent_lines":305,"n_total_lines":1208,"dependency_fraction":0.25248344370860926},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"TBP","stoichiometry":10.0},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"POLR1C","stoichiometry":0.2},{"gene":"POLR2F","stoichiometry":0.2},{"gene":"POLR2H","stoichiometry":0.2},{"gene":"POLR2K","stoichiometry":0.2},{"gene":"POLR3B","stoichiometry":0.2},{"gene":"POLR3F","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ZFP36L1","total_profiled":1310},"omim":[{"mim_id":"612053","title":"ZINC FINGER PROTEIN 36-LIKE 2; ZFP36L2","url":"https://www.omim.org/entry/612053"},{"mim_id":"604260","title":"SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5B; STAT5B","url":"https://www.omim.org/entry/604260"},{"mim_id":"601064","title":"ZINC FINGER PROTEIN 36-LIKE 1; ZFP36L1","url":"https://www.omim.org/entry/601064"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZFP36L1"},"hgnc":{"alias_symbol":["Berg36","ERF1","TIS11B","cMG1"],"prev_symbol":["BRF1"]},"alphafold":{"accession":"Q07352","domains":[{"cath_id":"-","chopping":"111-148","consensus_level":"medium","plddt":92.5908,"start":111,"end":148},{"cath_id":"-","chopping":"149-191","consensus_level":"medium","plddt":85.2423,"start":149,"end":191}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07352","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q07352-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q07352-F1-predicted_aligned_error_v6.png","plddt_mean":58.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZFP36L1","jax_strain_url":"https://www.jax.org/strain/search?query=ZFP36L1"},"sequence":{"accession":"Q07352","fasta_url":"https://rest.uniprot.org/uniprotkb/Q07352.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q07352/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07352"}},"corpus_meta":[{"pmid":"7664746","id":"PMC_7664746","title":"Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7664746","citation_count":487,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7556078","id":"PMC_7556078","title":"The products of the SUP45 (eRF1) and SUP35 genes interact to mediate translation termination in Saccharomyces cerevisiae.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7556078","citation_count":406,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10676813","id":"PMC_10676813","title":"The crystal structure of human eukaryotic release factor eRF1--mechanism of stop codon recognition and peptidyl-tRNA hydrolysis.","date":"2000","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/10676813","citation_count":372,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10445876","id":"PMC_10445876","title":"Mutations in the highly conserved GGQ motif of class 1 polypeptide release factors abolish ability of human eRF1 to trigger peptidyl-tRNA hydrolysis.","date":"1999","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10445876","citation_count":280,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25350841","id":"PMC_25350841","title":"Efficient multisite unnatural amino acid incorporation in mammalian cells via optimized pyrrolysyl tRNA synthetase/tRNA expression and engineered eRF1.","date":"2014","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/25350841","citation_count":223,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8634914","id":"PMC_8634914","title":"Eukaryotic polypeptide chain release factor eRF3 is an eRF1- and ribosome-dependent guanosine triphosphatase.","date":"1996","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8634914","citation_count":214,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23800963","id":"PMC_23800963","title":"Salt-responsive ERF1 regulates reactive oxygen species-dependent signaling during the initial response to salt stress in rice.","date":"2013","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/23800963","citation_count":207,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12198173","id":"PMC_12198173","title":"Functional cloning of BRF1, a regulator of ARE-dependent mRNA turnover.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12198173","citation_count":183,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14976220","id":"PMC_14976220","title":"Roles of AUF1 isoforms, HuR and BRF1 in ARE-dependent mRNA turnover studied by RNA interference.","date":"2004","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/14976220","citation_count":159,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27102483","id":"PMC_27102483","title":"RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence.","date":"2016","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/27102483","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19417105","id":"PMC_19417105","title":"Structural insights into eRF3 and stop codon recognition by eRF1.","date":"2009","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/19417105","citation_count":131,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15538381","id":"PMC_15538381","title":"The ARE-dependent mRNA-destabilizing activity of BRF1 is regulated by protein kinase B.","date":"2004","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15538381","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24424323","id":"PMC_24424323","title":"The wheat ethylene response factor transcription factor pathogen-induced ERF1 mediates host responses to both the necrotrophic pathogen Rhizoctonia cerealis and freezing stresses.","date":"2014","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24424323","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26745809","id":"PMC_26745809","title":"Arabidopsis ERF1 Mediates Cross-Talk between Ethylene and Auxin Biosynthesis during Primary Root Elongation by Regulating ASA1 Expression.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26745809","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9928949","id":"PMC_9928949","title":"C-terminal domains of human translation termination factors eRF1 and eRF3 mediate their in vivo interaction.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9928949","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11911360","id":"PMC_11911360","title":"Highly conserved NIKS tetrapeptide is functionally essential in eukaryotic translation termination factor eRF1.","date":"2002","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11911360","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9712840","id":"PMC_9712840","title":"Molecular cloning of a novel member of the eukaryotic polypeptide chain-releasing factors (eRF). Its identification as eRF3 interacting with eRF1.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9712840","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15467755","id":"PMC_15467755","title":"Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15467755","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10744022","id":"PMC_10744022","title":"Translation termination in eukaryotes: polypeptide release factor eRF1 is composed of functionally and structurally distinct domains.","date":"2000","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10744022","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9701287","id":"PMC_9701287","title":"The stretch of C-terminal acidic amino acids of translational release factor eRF1 is a primary binding site for eRF3 of fission yeast.","date":"1998","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9701287","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25561519","id":"PMC_25561519","title":"BRF1 mutations alter RNA polymerase III-dependent transcription and cause neurodevelopmental anomalies.","date":"2015","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/25561519","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24486019","id":"PMC_24486019","title":"Optimal translational termination requires C4 lysyl hydroxylation of eRF1.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/24486019","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34272367","id":"PMC_34272367","title":"A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34272367","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35294556","id":"PMC_35294556","title":"SALT AND ABA RESPONSE ERF1 improves seed germination and salt tolerance by repressing ABA signaling in rice.","date":"2022","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35294556","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9111351","id":"PMC_9111351","title":"Interaction between yeast Sup45p (eRF1) and Sup35p (eRF3) polypeptide chain release factors: implications for prion-dependent regulation.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9111351","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15509572","id":"PMC_15509572","title":"The glutamine residue of the conserved GGQ motif in Saccharomyces cerevisiae release factor eRF1 is methylated by the product of the YDR140w gene.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15509572","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25106868","id":"PMC_25106868","title":"ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK-RSK pathway.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25106868","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18180287","id":"PMC_18180287","title":"Structure of yeast Dom34: a protein related to translation termination factor Erf1 and involved in No-Go decay.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18180287","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12189178","id":"PMC_12189178","title":"Conversion of omnipotent translation termination factor eRF1 into ciliate-like UGA-only unipotent eRF1.","date":"2002","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/12189178","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18539146","id":"PMC_18539146","title":"HemK2 protein, encoded on human chromosome 21, methylates translation termination factor eRF1.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18539146","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10320572","id":"PMC_10320572","title":"The C-terminus of eRF1 defines a functionally important domain for translation termination in Saccharomyces cerevisiae.","date":"1999","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/10320572","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32059759","id":"PMC_32059759","title":"Nucleocytoplasmic Proteomic Analysis Uncovers eRF1 and Nonsense-Mediated Decay as Modifiers of ALS/FTD C9orf72 Toxicity.","date":"2020","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/32059759","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10887131","id":"PMC_10887131","title":"Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10887131","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30622281","id":"PMC_30622281","title":"RNA-binding protein ZFP36L1 regulates osteoarthritis by modulating members of the heat shock protein 70 family.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30622281","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10376874","id":"PMC_10376874","title":"C-terminal interaction of translational release factors eRF1 and eRF3 of fission yeast: G-domain uncoupled binding and the role of conserved amino acids.","date":"1999","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10376874","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9171074","id":"PMC_9171074","title":"Eukaryotic release factor 1 (eRF1) abolishes readthrough and competes with suppressor tRNAs at all three termination codons in messenger RNA.","date":"1997","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/9171074","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24046061","id":"PMC_24046061","title":"SALT-RESPONSIVE ERF1 is a negative regulator of grain filling and gibberellin-mediated seedling establishment in rice.","date":"2013","source":"Molecular plant","url":"https://pubmed.ncbi.nlm.nih.gov/24046061","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29426877","id":"PMC_29426877","title":"ZFP36L1 and ZFP36L2 inhibit cell proliferation in a cyclin D-dependent and p53-independent manner.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29426877","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9003791","id":"PMC_9003791","title":"The catalytic subunit of protein phosphatase 2A associates with the translation termination factor eRF1.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9003791","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21926091","id":"PMC_21926091","title":"Histone deacetylase HD2 interacts with ERF1 and is involved in longan fruit senescence.","date":"2011","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/21926091","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11788716","id":"PMC_11788716","title":"Convergence and constraint in eukaryotic release factor 1 (eRF1) domain 1: the evolution of stop codon specificity.","date":"2002","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/11788716","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17505538","id":"PMC_17505538","title":"Human Maf1 negatively regulates RNA polymerase III transcription via the TFIIB family members Brf1 and Brf2.","date":"2007","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17505538","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17008308","id":"PMC_17008308","title":"The zinc finger protein Ynr046w is plurifunctional and a component of the eRF1 methyltransferase in yeast.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17008308","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29238352","id":"PMC_29238352","title":"Overexpression of ERF1-V from Haynaldia villosa Can Enhance the Resistance of Wheat to Powdery Mildew and Increase the Tolerance to Salt and Drought Stresses.","date":"2017","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/29238352","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28891815","id":"PMC_28891815","title":"RNA-binding protein ZFP36L1 maintains posttranscriptional regulation of bile acid metabolism.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28891815","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31551365","id":"PMC_31551365","title":"RNA-Binding Protein ZFP36L1 Suppresses Hypoxia and Cell-Cycle Signaling.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31551365","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23435318","id":"PMC_23435318","title":"Two-step model of stop codon recognition by eukaryotic release factor eRF1.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/23435318","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16321977","id":"PMC_16321977","title":"The yeast translation release factors Mrf1p and Sup45p (eRF1) are methylated, respectively, by the methyltransferases Mtq1p and Mtq2p.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16321977","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31087059","id":"PMC_31087059","title":"The cold-induced transcription factor bHLH112 promotes artemisinin biosynthesis indirectly via ERF1 in Artemisia annua.","date":"2019","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/31087059","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8809766","id":"PMC_8809766","title":"Depletion in the levels of the release factor eRF1 causes a reduction in the efficiency of translation termination in yeast.","date":"1996","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/8809766","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34152677","id":"PMC_34152677","title":"ERF1 delays flowering through direct inhibition of FLOWERING LOCUS T expression in Arabidopsis.","date":"2021","source":"Journal of integrative plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/34152677","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11358506","id":"PMC_11358506","title":"The polypeptide chain release factor eRF1 specifically contacts the s(4)UGA stop codon located in the A site of eukaryotic ribosomes.","date":"2001","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11358506","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36631608","id":"PMC_36631608","title":"Short tRNA anticodon stem and mutant eRF1 allow stop codon reassignment.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/36631608","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17573528","id":"PMC_17573528","title":"Different modes of stop codon restriction by the Stylonychia and Paramecium eRF1 translation termination factors.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17573528","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12756323","id":"PMC_12756323","title":"Stop codon suppression via inhibition of eRF1 expression.","date":"2003","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12756323","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11157256","id":"PMC_11157256","title":"Expression of cmg1, an exo-beta-1,3-glucanase gene from Coniothyrium minitans, increases during sclerotial parasitism.","date":"2001","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/11157256","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19179481","id":"PMC_19179481","title":"cAMP-dependent posttranscriptional regulation of steroidogenic acute regulatory (STAR) protein by the zinc finger protein ZFP36L1/TIS11b.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19179481","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17526916","id":"PMC_17526916","title":"Arabidopsis enhanced ethylene response 4 encodes an EIN3-interacting TFIID transcription factor required for proper ethylene response, including ERF1 induction.","date":"2007","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/17526916","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28972307","id":"PMC_28972307","title":"Role of Brf1 interaction with ERα, and significance of its overexpression, in human breast cancer.","date":"2017","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28972307","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25014217","id":"PMC_25014217","title":"Post-transcriptional regulation of BCL2 mRNA by the RNA-binding protein ZFP36L1 in malignant B cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25014217","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22543865","id":"PMC_22543865","title":"Identification of eRF1 residues that play critical and complementary roles in stop codon recognition.","date":"2012","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/22543865","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20688868","id":"PMC_20688868","title":"Three distinct peptides from the N domain of translation termination factor eRF1 surround stop codon in the ribosome.","date":"2010","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20688868","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8898945","id":"PMC_8898945","title":"Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signaling through CD40 and interleukin-4 receptor: role for inhibition of an early response gene, Berg36.","date":"1996","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8898945","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36008402","id":"PMC_36008402","title":"Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36008402","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26701855","id":"PMC_26701855","title":"The significance of Brf1 overexpression in human hepatocellular carcinoma.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26701855","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12040026","id":"PMC_12040026","title":"Identification of two novel ACTH-responsive genes encoding manganese-dependent superoxide dismutase (SOD2) and the zinc finger protein TIS11b [tetradecanoyl phorbol acetate (TPA)-inducible sequence 11b].","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12040026","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20802528","id":"PMC_20802528","title":"A novel concept in antiangiogenic and antitumoral therapy: multitarget destabilization of short-lived mRNAs by the zinc finger protein ZFP36L1.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20802528","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28912018","id":"PMC_28912018","title":"Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer.","date":"2017","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/28912018","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20860996","id":"PMC_20860996","title":"A single amino acid change of translation termination factor eRF1 switches between bipotent and omnipotent stop-codon specificity.","date":"2010","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/20860996","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20702587","id":"PMC_20702587","title":"ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway.","date":"2010","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/20702587","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24277937","id":"PMC_24277937","title":"Mapping the protein interaction network for TFIIB-related factor Brf1 in the RNA polymerase III preinitiation complex.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24277937","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16227432","id":"PMC_16227432","title":"Reconfiguring the connectivity of a multiprotein complex: fusions of yeast TATA-binding protein with Brf1, and the function of transcription factor IIIB.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16227432","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25205575","id":"PMC_25205575","title":"Isolation and molecular characterization of ERF1, an ethylene response factor gene from durum wheat (Triticum turgidum L. subsp. durum), potentially involved in salt-stress responses.","date":"2014","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/25205575","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26180518","id":"PMC_26180518","title":"Functional regulation of Zfp36l1 and Zfp36l2 in response to lipopolysaccharide in mouse RAW264.7 macrophages.","date":"2015","source":"Journal of inflammation (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26180518","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19906736","id":"PMC_19906736","title":"GTP-dependent structural rearrangement of the eRF1:eRF3 complex and eRF3 sequence motifs essential for PABP binding.","date":"2009","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19906736","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27748960","id":"PMC_27748960","title":"BRF1 mutations in a family with growth failure, markedly delayed bone age, and central nervous system anomalies.","date":"2016","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27748960","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30526691","id":"PMC_30526691","title":"The RNA-binding proteins Zfp36l1 and Zfp36l2 act redundantly in myogenesis.","date":"2018","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/30526691","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18700021","id":"PMC_18700021","title":"Differential expression of the TFIIIB subunits Brf1 and Brf2 in cancer cells.","date":"2008","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18700021","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20166898","id":"PMC_20166898","title":"ZFP36L1 is regulated by growth factors and cytokines in keratinocytes and influences their VEGF production.","date":"2010","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/20166898","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27787902","id":"PMC_27787902","title":"UBC18 mediates ERF1 degradation under light-dark cycles.","date":"2016","source":"The New phytologist","url":"https://pubmed.ncbi.nlm.nih.gov/27787902","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15228544","id":"PMC_15228544","title":"Translation termination factors function outside of translation: yeast eRF1 interacts with myosin light chain, Mlc1p, to effect cytokinesis.","date":"2004","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/15228544","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33473330","id":"PMC_33473330","title":"The miR-93-3p/ZFP36L1/ZFX axis regulates keratinocyte proliferation and migration during skin wound healing.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/33473330","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26574598","id":"PMC_26574598","title":"Genetic Variation for Thermotolerance in Lettuce Seed Germination Is Associated with Temperature-Sensitive Regulation of ETHYLENE RESPONSE FACTOR1 (ERF1).","date":"2015","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26574598","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11179680","id":"PMC_11179680","title":"The ciliate Euplotes octocarinatus expresses two polypeptide release factors of the type eRF1.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11179680","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19801654","id":"PMC_19801654","title":"Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma: impact on vascular endothelial growth factor expression in hypoxia.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19801654","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15871044","id":"PMC_15871044","title":"Decoding the decoding region: analysis of eukaryotic release factor (eRF1) stop codon-binding residues.","date":"2005","source":"Journal of molecular evolution","url":"https://pubmed.ncbi.nlm.nih.gov/15871044","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24733888","id":"PMC_24733888","title":"Brf1 posttranscriptionally regulates pluripotency and differentiation responses downstream of Erk MAP kinase.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24733888","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28062855","id":"PMC_28062855","title":"Expression of the eRF1 translation termination factor is controlled by an autoregulatory circuit involving readthrough and nonsense-mediated decay in plants.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28062855","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15475364","id":"PMC_15475364","title":"Release factors eRF1 and RF2: a universal mechanism controls the large conformational changes.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15475364","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10471834","id":"PMC_10471834","title":"Polypeptide release factor eRF1 from Tetrahymena thermophila: cDNA cloning, purification and complex formation with yeast eRF3.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10471834","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17877750","id":"PMC_17877750","title":"Vaccinia virus-mediated cell cycle alteration involves inactivation of tumour suppressors associated with Brf1 and TBP.","date":"2007","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/17877750","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1628738","id":"PMC_1628738","title":"Mitogen-induced expression of the primary response gene cMG1 in a rat intestinal epithelial cell-line (RIE-1).","date":"1992","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/1628738","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33306108","id":"PMC_33306108","title":"Efficient homing of antibody-secreting cells to the bone marrow requires RNA-binding protein ZFP36L1.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33306108","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16551611","id":"PMC_16551611","title":"Mapping the principal interaction site of the Brf1 and Bdp1 subunits of Saccharomyces cerevisiae TFIIIB.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16551611","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37450369","id":"PMC_37450369","title":"The ABI3-ERF1 module mediates ABA-auxin crosstalk to regulate lateral root emergence.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37450369","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27531991","id":"PMC_27531991","title":"Regulation of StAR by the N-terminal Domain and Coinduction of SIK1 and TIS11b/Znf36l1 in Single Cells.","date":"2016","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27531991","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37224012","id":"PMC_37224012","title":"ERF1 inhibits lateral root emergence by promoting local auxin accumulation and repressing ARF7 expression.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37224012","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17651434","id":"PMC_17651434","title":"Eukaryotic class 1 translation termination factor eRF1--the NMR structure and dynamics of the middle domain involved in triggering ribosome-dependent peptidyl-tRNA hydrolysis.","date":"2007","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/17651434","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11996793","id":"PMC_11996793","title":"Evaluation of ETF1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene.","date":"2002","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11996793","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12930823","id":"PMC_12930823","title":"The Brf1 and Bdp1 subunits of transcription factor TFIIIB bind to overlapping sites in the tetratricopeptide repeats of Tfc4.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12930823","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23128233","id":"PMC_23128233","title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23128233","citation_count":3725,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21833088","id":"PMC_21833088","title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21833088","citation_count":2101,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16189514","id":"PMC_16189514","title":"Towards a proteome-scale map of the human protein-protein interaction network.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16189514","citation_count":2090,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21102463","id":"PMC_21102463","title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21102463","citation_count":2036,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19430480","id":"PMC_19430480","title":"Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19430480","citation_count":1382,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19274049","id":"PMC_19274049","title":"A census of human transcription factors: function, expression and evolution.","date":"2009","source":"Nature reviews. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19274049","citation_count":1191,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20190752","id":"PMC_20190752","title":"Multiple common variants for celiac disease influencing immune gene expression.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20190752","citation_count":801,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23535732","id":"PMC_23535732","title":"Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23535732","citation_count":463,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15687258","id":"PMC_15687258","title":"Recruitment and activation of mRNA decay enzymes by two ARE-mediated decay activation domains in the proteins TTP and BRF-1.","date":"2005","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15687258","citation_count":410,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15146197","id":"PMC_15146197","title":"Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation.","date":"2004","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/15146197","citation_count":266,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17369404","id":"PMC_17369404","title":"TTP and BRF proteins nucleate processing body formation to silence mRNAs with AU-rich elements.","date":"2007","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/17369404","citation_count":200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19417104","id":"PMC_19417104","title":"SMG-8 and SMG-9, two novel subunits of the SMG-1 complex, regulate remodeling of the mRNA surveillance complex during nonsense-mediated mRNA decay.","date":"2009","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/19417104","citation_count":198,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26673895","id":"PMC_26673895","title":"A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.","date":"2015","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26673895","citation_count":198,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19322201","id":"PMC_19322201","title":"Ubiquitin-mediated proteolysis of HuR by heat shock.","date":"2009","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/19322201","citation_count":142,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21278925","id":"PMC_21278925","title":"The roles of TTP and BRF proteins in regulated mRNA decay.","date":"2011","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/21278925","citation_count":132,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21044950","id":"PMC_21044950","title":"Genome-wide YFP fluorescence complementation screen identifies new regulators for telomere signaling in human cells.","date":"2010","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/21044950","citation_count":93,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20967262","id":"PMC_20967262","title":"Expression of conjoined genes: another mechanism for gene regulation in eukaryotes.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20967262","citation_count":85,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17030608","id":"PMC_17030608","title":"BRF1 protein turnover and mRNA decay activity are regulated by protein kinase B at the same phosphorylation sites.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17030608","citation_count":79,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26972000","id":"PMC_26972000","title":"Substrate-Trapped Interactors of PHD3 and FIH Cluster in Distinct Signaling Pathways.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26972000","citation_count":77,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18326031","id":"PMC_18326031","title":"The AU-rich element mRNA decay-promoting activity of BRF1 is regulated by mitogen-activated protein kinase-activated protein kinase 2.","date":"2008","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18326031","citation_count":72,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48803,"output_tokens":5465,"usd":0.114192},"stage2":{"model":"claude-opus-4-6","input_tokens":9022,"output_tokens":6699,"usd":0.318877},"total_usd":0.839963,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":61103,"output_tokens":9657,"usd":0.164082},"round2_rules_fired":"R2","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12390,"output_tokens":3997,"usd":0.242812}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"ZFP36L1 (BRF1/TIS11b) was identified as an essential regulator of ARE-dependent mRNA decay; its CCCH zinc fingers are required for ARE binding and mRNA destabilization activity, and loss-of-function mutations in both alleles abolish rapid mRNA decay in a cell line. Independent siRNA knockdown confirmed its active role in degrading ARE-containing mRNAs.\",\n      \"method\": \"Functional cloning/retroviral rescue screen, siRNA knockdown, transfection with zinc-finger mutants, ARE-reporter fluorescence assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (genetic rescue, siRNA, mutant) in single rigorous study\",\n      \"pmids\": [\"12198173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZFP36L1 (BRF1) mRNA-destabilizing activity is regulated by protein kinase B (PKB/Akt), which phosphorylates BRF1 at serine 92. This phosphorylation does not impair ARE binding but induces complex formation with the scaffold protein 14-3-3, inactivating BRF1 and stabilizing ARE-mRNAs. In vitro reconstituted mRNA decay assays confirmed that phosphorylated BRF1 has impaired destabilizing activity.\",\n      \"method\": \"In vitro ARE-mRNA decay assay, site-directed mutagenesis (S92), in vivo and in vitro 14-3-3 co-immunoprecipitation, recombinant protein phosphorylation\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro reconstitution plus mutagenesis plus Co-IP, multiple orthogonal methods\",\n      \"pmids\": [\"15538381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZFP36L1 (TIS11b) binds directly to two UAUUUAUU AU-rich motifs in the extended 3'-UTR of the 3.5-kb StAR mRNA and promotes its destabilization; AURE mutations abolished the destabilizing effect. siRNA knockdown of ZFP36L1 specifically enhanced cAMP-stimulated 3.5-kb StAR mRNA expression.\",\n      \"method\": \"Direct RNA complex formation assay, cotransfection luciferase-3'UTR reporters, AURE mutagenesis, siRNA knockdown\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding demonstrated with AURE mutagenesis and confirmed by siRNA, multiple orthogonal methods\",\n      \"pmids\": [\"19179481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZFP36L1 (TIS11b) destabilizes VEGF mRNA by binding to a 75 bp domain containing two consensus AU-rich motifs within the VEGF 3'-UTR, reducing VEGF mRNA half-life from ~130 to ~60 min. RNP immunoprecipitation showed the interaction occurs in live cells; siRNA knockdown of TIS11b elevated VEGF mRNA in primary adrenocortical cells.\",\n      \"method\": \"RNA half-life assay, RNP immunoprecipitation, siRNA knockdown, 3'-UTR binding domain mapping\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal in-cell RNP-IP, domain mapping, siRNA, multiple orthogonal methods\",\n      \"pmids\": [\"15467755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZFP36L1 (BRF1) siRNA knockdown increased ARE-mRNA reporter fluorescence (stabilizing ARE-mRNAs), opposite to the effect of HuR knockdown, demonstrating antagonistic control of ARE-mRNA stability between ZFP36L1 and HuR.\",\n      \"method\": \"siRNA knockdown, fluorescent ARE-reporter assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with defined reporter readout, single lab, single main method\",\n      \"pmids\": [\"14976220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZFP36L1 (TIS11b/ZFP36L1) binds to UAUUUAUU repeats in the extended 3'-UTR of StAR mRNA, forming a direct complex, and promotes destabilization; this is rapidly induced by cAMP/ACTH signaling and closely follows the peak of StAR mRNA induction.\",\n      \"method\": \"Direct RNA complex formation, cotransfection reporters, siRNA, mRNA half-life measurement\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding plus siRNA confirmation, single lab\",\n      \"pmids\": [\"19179481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by directly binding to the 3'-UTR of Stat5b mRNA and triggering its degradation; overexpression of ZFP36L1 decreases Stat5b levels and erythroid colony formation, confirmed by Stat5b-targeted siRNA and pharmacological induction of ZFP36L1.\",\n      \"method\": \"3'-UTR binding assay, overexpression, siRNA, erythroid colony formation assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct binding plus loss/gain of function with defined phenotype, single lab\",\n      \"pmids\": [\"20702587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZFP36L1 (TIS11b) destabilizes multiple angiogenic and inflammatory cytokine mRNAs (including VEGF, FGF-a, TNF-α, IL-1α, IL-6) through its ARE-binding activity; protein transduction domain-fused ZFP36L1 introduced into cells reduced VEGF mRNA half-life, and intratumoral injection reduced tumor growth and vascularization in mice.\",\n      \"method\": \"Protein transduction/cell penetrating fusion protein delivery, in vivo mouse tumor model, mRNA half-life assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vivo functional consequence plus in vitro mRNA decay, single lab\",\n      \"pmids\": [\"20802528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZFP36L1 and ZFP36L2 bind to the 3'-UTR of LDLR mRNA and recruit the CCR4-NOT deadenylase complex, destabilizing LDLR mRNA. The C-terminal regions of ZFP36L1 and ZFP36L2 are directly phosphorylated by RSK (p90 ribosomal S6 kinase, downstream of ERK), causing dissociation of the CCR4-NOT complex and stabilization of LDLR mRNA.\",\n      \"method\": \"Proteomic RNA pull-down, Co-IP of CCR4-NOT, in vitro kinase assay (RSK phosphorylation), mRNA stability assay, antisense oligonucleotide disruption\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — proteomic identification, direct in vitro phosphorylation, functional complex dissociation, multiple methods\",\n      \"pmids\": [\"25106868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZFP36L1 (Brf1) acts downstream of FGF/ERK MAP kinase signaling in mouse embryonic stem cells; FGF/ERK signaling upregulates Brf1, which directly destabilizes Nanog mRNA and disrupts core pluripotency gene expression. Brf1 overexpression accelerates mesendoderm commitment during differentiation.\",\n      \"method\": \"Overexpression, mRNA stability assay, genetic epistasis with ERK pathway inhibitors, differentiation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis plus direct target mRNA decay demonstrated, single lab\",\n      \"pmids\": [\"24733888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZFP36L1 and ZFP36L2 are required for maintaining quiescence of developing B lymphocytes before pre-BCR expression and for reestablishing quiescence after pre-BCR-induced expansion. These RNA-binding proteins suppress a posttranscriptional regulon of mRNAs encoding proteins that cooperatively promote S-phase entry, thereby enabling VDJ recombination.\",\n      \"method\": \"Conditional knockout mice, cell cycle analysis, RNA-binding target identification\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with defined molecular phenotype (mRNA targets + cell cycle arrest), replicated with ZFP36L2\",\n      \"pmids\": [\"27102483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZFP36L1 is an FXR (farnesoid X receptor) target gene; gain and loss of ZFP36L1 function reciprocally regulate Cyp7a1 mRNA levels and bile acid metabolism in vivo. ZFP36L1 mediates rapid posttranscriptional degradation of Cyp7a1 mRNA upon FXR activation.\",\n      \"method\": \"Conditional liver-specific knockout mice, gain-of-function overexpression, in vivo bile acid measurement, mRNA stability assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal in vivo gain/loss of function with defined molecular and metabolic phenotype\",\n      \"pmids\": [\"28891815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZFP36L1 (and ZFP36L2) overexpression inhibits cell proliferation and arrests the cell cycle at G1 in a cyclin D-dependent and p53-independent manner; mutation of the tandem zinc finger (TZF) domain abolishes their ability to inhibit cyclin D expression and antiproliferative function.\",\n      \"method\": \"Overexpression, siRNA knockdown, TZF domain mutagenesis, cell cycle analysis across multiple cell lines including p53-null cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — TZF mutagenesis linking RNA-binding to antiproliferative function, single lab, multiple cell lines\",\n      \"pmids\": [\"29426877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZFP36L1 binds to the 3'-UTRs of HIF1A, CCND1, and E2F1 mRNAs via its zinc finger domains and promotes their degradation; wild-type but not zinc-finger mutant ZFP36L1 bound HIF1A 3'UTR and mediated its decay, suppressing hypoxia signaling.\",\n      \"method\": \"RNA pull-down (WT vs. mutant ZFP36L1), whole transcriptome sequencing, dual luciferase reporter assay, RNA EMSA\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding with mutant controls plus reporter assay, single lab\",\n      \"pmids\": [\"31551365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZFP36L1 in OA chondrocytes directly targets and destabilizes mRNAs of two HSP70 family members (HSPA1A and related), which act as protective factors against chondrocyte apoptosis. Knockdown of Zfp36l1 increased HSP70 mRNA expression and protected against experimental osteoarthritis in mice.\",\n      \"method\": \"Adenovirus-mediated overexpression, genetic ablation (knockout mice), siRNA knockdown, mRNA stability assay, in vivo OA model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO with defined OA phenotype plus direct mRNA target identification, multiple methods\",\n      \"pmids\": [\"30622281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ZFP36L1 regulates MKP-1 (Mkp-1) mRNA stability by binding to its ARE, maintaining its half-life. Phosphorylation of ZFP36L1 (during LPS stimulation) promotes complex formation with 14-3-3 and decreases interaction with deadenylase Caf1a, stabilizing Mkp-1 mRNA and inhibiting p38 MAPK activity.\",\n      \"method\": \"siRNA knockdown, mRNA half-life measurement, 14-3-3 co-immunoprecipitation, Caf1a interaction assay\",\n      \"journal\": \"Journal of inflammation (London, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP and siRNA with defined mRNA target, single lab\",\n      \"pmids\": [\"26180518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZFP36L1 (Brf1) directly destabilizes Nanog mRNA in mouse embryonic stem cells downstream of FGF/ERK signaling, attenuating self-renewal; this represents a posttranscriptional mechanism by which ERK activation rapidly disrupts pluripotency gene expression.\",\n      \"method\": \"mRNA stability assay, overexpression/knockdown, epistasis with ERK pathway inhibitors\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mRNA decay measurement plus pathway epistasis, single lab\",\n      \"pmids\": [\"24733888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZFP36L1 facilitates homing of antibody-secreting cells (ASCs) to the bone marrow by directly regulating (destabilizing) mRNAs encoding G protein-coupled receptor kinase 2 (GRK2) and integrin chains α4 and β1 in splenic ASCs; ZFP36L1 deletion causes ASC accumulation in spleen and liver with diminished bone marrow homing.\",\n      \"method\": \"Conditional gene deletion, in vivo ASC homing assay, direct RNA-binding confirmation\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined homing phenotype plus direct mRNA target identification, single lab\",\n      \"pmids\": [\"33306108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZFP36L1 binds and destabilizes SOX2 and INSM1 mRNAs (transcription factors required for SCLC neuroendocrine differentiation). ZFP36L1 is repressed by LSD1 (histone demethylase), and upon LSD1 inhibition, restored ZFP36L1 expression blocks neuroendocrine differentiation and induces a non-neuroendocrine inflammatory phenotype in SCLC.\",\n      \"method\": \"CRISPR/Cas9 screen, mRNA decay assay, RNA-binding assays, LSD1 ChIP/occupancy, overexpression phenotypic rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide CRISPR screen plus direct mRNA target functional validation, single lab\",\n      \"pmids\": [\"36008402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZFP36L1 targets BCL2 mRNA via its 3'-UTR ARE; wild-type but not zinc-finger mutant ZFP36L1 bound BCL2 ARE by RNA EMSA, and ZFP36L1 knockdown in B-cell lines delayed BCL2 mRNA degradation and increased BCL2 mRNA levels.\",\n      \"method\": \"RNA EMSA, shRNA knockdown, mRNA half-life measurement, 3'-UTR luciferase reporter assay with ARE deletion mutants\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct binding (EMSA) plus reporter assay with mutant controls, single lab\",\n      \"pmids\": [\"25014217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"ZFP36L1 (Berg36) was implicated as a pro-apoptotic factor in Ramos human B cells induced by calcium ionophore; antisense blockade of Berg36 expression partially inhibited ionophore-induced apoptosis, and IL-4 protection from apoptosis correlated with inhibition of Berg36 expression.\",\n      \"method\": \"Antisense blockade, apoptosis assay, IL-4 cytokine treatment\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single antisense approach, limited mechanistic resolution\",\n      \"pmids\": [\"8898945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In keratinocytes, miR-93-3p directly targets ZFP36L1 (reducing its expression), and ZFP36L1 in turn directly targets ZFX mRNA for degradation; silencing ZFP36L1 promoted keratinocyte proliferation and migration, mirroring miR-93-3p overexpression, establishing a miR-93-3p/ZFP36L1/ZFX regulatory axis.\",\n      \"method\": \"miRNA target validation, siRNA knockdown, in vivo wound model, proliferation/migration assays\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — functional knockdown with phenotype but limited direct ZFX binding evidence\",\n      \"pmids\": [\"33473330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZFP36L1 and ZFP36L2 act redundantly in myogenesis; double conditional knockout of Zfp36l1 and Zfp36l2 in Pax7-expressing satellite cells reduces satellite cell number, skeletal muscle mass, and regenerative capacity after injury.\",\n      \"method\": \"Conditional double knockout mice (Pax7-Cre), muscle injury model (cardiotoxin), immunostaining, muscle mass measurement\",\n      \"journal\": \"Skeletal muscle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — double conditional KO with defined cellular and tissue phenotype, single lab\",\n      \"pmids\": [\"30526691\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZFP36L1 is an RNA-binding protein containing tandem CCCH zinc finger domains that binds AU-rich elements (AREs) in the 3'-UTRs of target mRNAs (including VEGF, LDLR, Cyp7a1, HIF1A, CCND1, Nanog, BCL2, Stat5b, SOX2, INSM1, and HSP70 family members) and recruits the CCR4-NOT deadenylase complex to promote mRNA degradation; its destabilizing activity is inhibited by phosphorylation (by PKB/Akt at S92 or by RSK downstream of ERK), which induces binding to 14-3-3 scaffold proteins and dissociation from deadenylase complexes, thereby stabilizing target mRNAs, while in lymphocyte development it maintains quiescence by suppressing a regulon of cell-cycle-promoting mRNAs.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**Classification:**\n\nThe target gene is ZFP36L1 (also known as BRF1/TIS11b/cMG1/Berg36/ERF-1 in the ZFP36 family context — NOT eRF1 the translation release factor, NOT BRF1 the RNA Pol III transcription factor, NOT plant ERF1 transcription factors).\n\n**EXCLUDE (alias collisions or unrelated):**\n- Papers [1-6, 11, 15-16, 19-20, 22-23, 25-32, 34-36, 38-41, 43, 47, 50, 52-55, 61-62, 69, 75, 81, 84, 86-90, 98-99] — these are about eRF1/eRF3 (translation termination factors)\n- Papers [7, 13-14, 24, 37, 40, 44, 49, 51, 58, 73, 80, 83, 95, 97] — plant ERF1 (ethylene response factor, completely different protein)\n- Papers [21, 42, 59, 65, 68, 71-72, 76, 78, 91, 94, 100] — BRF1 as RNA Pol III transcription factor (TFIIB-related factor 1, different protein)\n- Paper [56] — cmg1 fungal glucanase (symbol collision)\n\n**KEEP (canonical ZFP36L1 papers):**\n- [8] BRF1 = ZFP36L1, functional cloning in mRNA turnover\n- [9] BRF1 = ZFP36L1, ARE-dependent mRNA turnover\n- [10] ZFP36L1 and ZFP36L2 promote cell quiescence\n- [12] BRF1 (ZFP36L1) regulated by PKB/Akt\n- [17] TIS11b = ZFP36L1, mRNA destabilization of VEGF\n- [18] TIS11b = ZFP36L1, VEGF mRNA destabilization — WAIT, paper [18] is PMID:15467755, TIS11b destabilizes VEGF mRNA — KEEP\n- [27] ZFP36L1 and ZFP36L2 control LDLR mRNA stability via ERK-RSK\n- [33] TIS11b (ERF-1, cMG1) = ZFP36L1 — KEEP\n- [34] ZFP36L1 regulates osteoarthritis via HSP70\n- [38] ZFP36L1 and ZFP36L2 inhibit cell proliferation via cyclin D\n- [45] ZFP36L1 regulates bile acid metabolism\n- [46] ZFP36L1 suppresses hypoxia and cell-cycle signaling\n- [57] ZFP36L1/TIS11b regulates StAR mRNA\n- [60] ZFP36L1 regulates BCL2 mRNA\n- [63] Berg36 = ZFP36L1 in B cells\n- [64] ZFP36L1 regulates neuroendocrine plasticity\n- [67] ZFP36L1 as antiangiogenic/antitumoral agent\n- [70] ZFP36L1 negatively regulates erythroid differentiation via Stat5b\n- [74] Zfp36l1 and Zfp36l2 in LPS response in macrophages\n- [77] Zfp36l1 and Zfp36l2 act redundantly in myogenesis\n- [79] ZFP36L1 regulated by growth factors in keratinocytes\n- [82] miR-93-3p/ZFP36L1/ZFX axis in wound healing\n- [85] TIS11B (ZFP36L1) modulates VEGF in renal cancer — KEEP\n- [92] cMG1 = ZFP36L1 primary response gene — KEEP\n- [93] ZFP36L1 in ASC homing to bone marrow\n- [96] TIS11b/Znf36l1 in StAR regulation — KEEP\n\n**Additional curated papers:**\n- [17] (Lykke-Andersen 2005) BRF-1 recruits mRNA decay enzymes — KEEP\n- [18] (Franks 2007) TTP and BRF-1 nucleate PBs — KEEP  \n- [21] (TTP and BRF proteins in regulated mRNA decay) — KEEP\n- [25] (Sanduja 2011) TIS11 family roles — KEEP\n- [28] (Benjamin 2006) BRF1 phosphorylation by PKB — KEEP\n- [30] (Maitra 2008) BRF1 phosphorylated by MK2 — KEEP\n\nNow extracting discoveries:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"ZFP36L1 (BRF1) was functionally identified as an essential regulator of AU-rich element (ARE)-dependent mRNA decay. Genetic rescue of a mutant cell line (slowC) deficient in ARE-mRNA degradation by retroviral cDNA library screening identified BRF1 as the causative gene; slowC carried frame-shift mutations in both BRF1 alleles. siRNA knockdown and transfection experiments confirmed that BRF1 accelerates ARE-mRNA decay and that its zinc-finger domains are required for both ARE binding and mRNA destabilization activity.\",\n      \"method\": \"Retroviral cDNA library functional rescue screen, flow cytometry of GFP-ARE reporter, siRNA knockdown, zinc-finger mutagenesis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including genetic rescue, mutagenesis of zinc fingers, and siRNA in the same study; independently corroborated\",\n      \"pmids\": [\"12198173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZFP36L1 (BRF1) mRNA-destabilizing activity is regulated by protein kinase B (PKB/Akt), which phosphorylates BRF1 at serine 92 (S92). Phosphorylation by PKB impairs BRF1's in vitro ARE-mRNA decay activity without affecting ARE binding, but induces complex formation with the scaffold protein 14-3-3, sequestering BRF1 and stabilizing ARE-containing transcripts.\",\n      \"method\": \"In vitro mRNA decay assay with recombinant BRF1, in vitro kinase assay, co-immunoprecipitation with 14-3-3, site-directed mutagenesis (S92A)\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstituted in vitro decay assay plus mutagenesis plus 14-3-3 co-IP; multiple orthogonal methods in one study\",\n      \"pmids\": [\"15538381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZFP36L1 (TIS11b) binds to AU-rich elements in the 3'-UTR of VEGF mRNA and destabilizes it, reducing VEGF mRNA half-life from ~130 to ~60 min. A 75 bp domain containing two consensus AU-rich motifs was identified as the binding and destabilization target. RNP immunoprecipitation confirmed the interaction in live cells, and siRNA knockdown of TIS11b elevated VEGF mRNA levels in primary adrenocortical cells.\",\n      \"method\": \"mRNA half-life measurements, RNP immunoprecipitation, deletion mapping of 3'-UTR, siRNA knockdown\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (half-life, RNP-IP, siRNA) with functional validation in primary cells\",\n      \"pmids\": [\"15467755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZFP36L1 (BRF1) and TTP each contain two activation domains that recruit mRNA decay enzymes (deadenylases, decapping enzymes, and exonucleases) involved in deadenylation, decapping, and 3'-to-5' and 5'-to-3' exonucleolytic decay. BRF-1's N-terminal activation domain functions as a binding platform for mRNA decay machinery, linking ARE-containing mRNAs to the decay apparatus.\",\n      \"method\": \"Co-immunoprecipitation of decay enzymes with BRF-1, tethered mRNA decay assays with heterologous RNA-binding domain fusions, dominant-negative overexpression\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP of multiple decay enzymes, functional tethering assays, confirmed with dominant-negative mutants\",\n      \"pmids\": [\"15687258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"siRNA-mediated knockdown of BRF1 (ZFP36L1) stabilized ARE-reporter mRNA and increased fluorescence of a GFP-ARE reporter in HT1080 cells, confirming its endogenous role as an ARE-mRNA destabilizer. Selective knockdown of p40AUF1/p45AUF1 but not BRF1 stabilized GM-CSF mRNA, demonstrating that BRF1 and AUF1 regulate overlapping but distinct ARE-mRNA subsets.\",\n      \"method\": \"siRNA knockdown, fluorescent ARE-reporter assay, GM-CSF mRNA stability measurement\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean siRNA KD with quantitative reporter readout, but single lab\",\n      \"pmids\": [\"14976220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BRF1 (ZFP36L1) protein stability and mRNA decay activity are co-regulated by PKB/Akt phosphorylation at two cooperative sites, S92 and S203. Phosphorylation at both sites is required for 14-3-3 binding, BRF1 protein stabilization (preventing proteasomal degradation), and inactivation of ARE-mRNA decay. Alanine mutations at both sites uncoupled BRF1 from PKB regulation, causing constitutive mRNA decay. BRF1 is labile (half-life <3 h) and stabilized by phosphorylation-dependent 14-3-3 binding.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis (S92A/S203A), proteasome inhibitor experiments, cell fractionation, PKBα knockout cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay plus mutagenesis plus genetic (PKBα KO cells), multiple orthogonal approaches\",\n      \"pmids\": [\"17030608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ZFP36L1 (BRF-1) and TTP deliver ARE-mRNAs to processing bodies (PBs) in human cells. Depletion of endogenous TTP and BRF proteins impaired localization of ARE-reporter mRNAs to PBs. BRF-1 can tether mRNAs to PBs and TTP can nucleate PB formation on untranslated mRNAs. ARE-mRNA PB localization requires the TTP/BRF-1 N- and C-terminal domains and occurs downstream of mRNA polysome release.\",\n      \"method\": \"siRNA depletion, fluorescent reporter mRNA tracking, dominant-negative overexpression, tethering assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (depletion, tethering, live imaging), replicated across labs\",\n      \"pmids\": [\"17369404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ZFP36L1 (BRF1) is phosphorylated by MAPK-activated protein kinase 2 (MK2) at four sites including S54, S92, and S203, which inhibits its ARE-mRNA decay activity. This inhibition does not alter BRF1's ability to bind AREs or associate with mRNA decay enzymes, suggesting MK2 targets a step downstream of RNA binding and decay enzyme recruitment.\",\n      \"method\": \"In vitro kinase assay with BRF1 fragments, co-expression of active MK2, ARE-mRNA decay assays, mutagenesis of phosphorylation sites\",\n      \"journal\": \"RNA\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with defined substrates, mutagenesis mapping, functional ARE-decay assay\",\n      \"pmids\": [\"18326031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZFP36L1 (TIS11b) regulates steroidogenic acute regulatory protein (StAR) mRNA stability through direct binding to UAUUUAUU AU-rich repeats in the extended 3'-UTR of the 3.5-kb StAR transcript. Cotransfection of TIS11b selectively decreased cytomegalovirus-driven Star mRNA and luciferase-Star 3'-UTR reporters. siRNA knockdown of TIS11b specifically enhanced 3.5-kb Star mRNA induction and halved STAR protein induction, demonstrating coupling of mRNA decay to cholesterol metabolism in steroidogenic cells.\",\n      \"method\": \"Direct RNA complex formation assay, luciferase-3'UTR reporter assay, siRNA knockdown, ARE mutagenesis, cotransfection\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (RIP, reporter assay with ARE mutations, siRNA) linking ZFP36L1 to specific physiological outcome\",\n      \"pmids\": [\"19179481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZFP36L1 (TIS11b/ZFP36L1) expression is regulated by VHL tumor suppressor protein in renal cancer cells. In normoxia, VHL overexpression increased hsa-miR-29b levels, which decreased TIS11B protein by post-transcriptional regulation. In hypoxia, VHL overexpression increased TIS11B mRNA stability and protein levels, which in turn downregulated VEGF mRNA. Silencing TIS11B reversed VHL-mediated VEGF downregulation in hypoxia.\",\n      \"method\": \"miRNA expression analysis, TIS11B knockdown with siRNA, VEGF mRNA and protein quantification, TIS11B mRNA stability assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — knockdown with functional readout (VEGF mRNA levels), single lab, multiple methods\",\n      \"pmids\": [\"19801654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by directly binding the 3'-UTR of Stat5b mRNA to trigger its degradation, thereby reducing STAT5B protein levels. ZFP36L1 overexpression dramatically decreased erythroid colony formation in human hematopoietic progenitors, and this effect was confirmed by Stat5b siRNA knockdown. Co-overexpression of ZFP36L1 and ZFP36 had a cumulative effect on Stat5b downregulation.\",\n      \"method\": \"3'-UTR RNA binding assay, overexpression in CD34+ cells, erythroid colony assay, siRNA knockdown of Stat5b, co-overexpression experiments\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — direct 3'UTR binding plus functional colony assay plus siRNA epistasis, single lab\",\n      \"pmids\": [\"20702587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cell-penetrating fusion proteins of ZFP36L1 (R9-ZFP36L1, TAT-ZFP36L1) were efficiently internalized into living cells and decreased endogenous VEGF mRNA half-life and VEGF protein levels. Intratumoral injection of R9-ZFP36L1 in Lewis Lung Carcinoma mouse models significantly reduced tumor growth and decreased expression of multiple angiogenic and inflammatory cytokines (VEGF, FGF-a, TNFα, IL-1α, IL-6), with concomitant reduction in tumor vascularization.\",\n      \"method\": \"Protein transduction domain fusion constructs, in vitro mRNA decay assays, intratumoral injection in mouse tumor model, cytokine quantification\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional in vitro and in vivo experiments with exogenous ZFP36L1 protein, single lab\",\n      \"pmids\": [\"20802528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZFP36L1 (ZFP36L1) is induced by growth factors and cytokines in keratinocytes (EGF, FGF, serum, etc.) and by scratch wounding. siRNA-mediated knockdown of ZFP36L1 in HaCaT keratinocytes prolonged elevated VEGF mRNA levels following EGF stimulation, consistent with ZFP36L1 destabilizing VEGF mRNA in the wound healing context.\",\n      \"method\": \"siRNA knockdown, VEGF mRNA quantification, scratch wound assay\",\n      \"journal\": \"Growth factors\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — siRNA knockdown with mRNA readout, single method, single lab\",\n      \"pmids\": [\"20166898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZFP36L1 (Brf1) operates downstream of FGF/ERK MAP kinase signaling in mouse embryonic stem cells (mESCs) to regulate pluripotency by destabilizing target mRNAs including Nanog. FGF/ERK signaling upregulates Brf1, which disrupts core pluripotency gene expression and attenuates mESC self-renewal. Brf1 overexpression preferentially regulates mesendoderm commitment during differentiation, accelerating primitive streak marker expression.\",\n      \"method\": \"Conditional Brf1 overexpression in mESCs, mRNA stability assays (Nanog half-life), ERK pathway manipulation, differentiation assays with lineage markers\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mRNA stability measurements, genetic overexpression, epistasis with ERK pathway, single lab\",\n      \"pmids\": [\"24733888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZFP36L1 and ZFP36L2 bind to the 3'-UTR of LDLR mRNA and recruit the CCR4-NOT deadenylase complex, destabilizing LDLR mRNA. The C-terminal regions of ZFP36L1 and ZFP36L2 are directly phosphorylated by p90 ribosomal S6 kinase (RSK, downstream of ERK), causing dissociation of the CCR4-NOT complex and stabilization of LDLR mRNA. Antisense oligonucleotides targeting the ZFP36L1/L2 binding sites on LDLR mRNA upregulated LDLR mRNA and protein.\",\n      \"method\": \"Proteomic identification of 3'-UTR binding proteins (pull-down MS), CCR4-NOT co-immunoprecipitation, in vitro phosphorylation by RSK, antisense oligonucleotide experiments\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — proteomic identification plus co-IP of CCR4-NOT complex plus in vitro kinase assay, multiple orthogonal methods\",\n      \"pmids\": [\"25106868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZFP36L1 (ZFP36L1) binds the BCL2 3'-UTR AU-rich element and mediates BCL2 mRNA degradation in malignant B cells. RNA electrophoretic mobility shift assay (REMSA) showed direct ZFP36L1-BCL2 ARE interaction. ZFP36L1 knockdown in BCL1, ACHN, and Ramos cells increased BCL2 mRNA levels. Luciferase reporter assays showed wild-type but not zinc-finger mutant ZFP36L1 downregulated BCL2 ARE-containing constructs; deletion of the ARE core abrogated this effect.\",\n      \"method\": \"RNA EMSA, siRNA/shRNA knockdown in multiple cell lines, 3'UTR luciferase reporter assay, zinc-finger domain mutagenesis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — EMSA plus reporter assay with mutagenesis plus knockdown in multiple cell types, single lab\",\n      \"pmids\": [\"25014217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In LPS-stimulated RAW264.7 macrophages, ZFP36L1 protein is hyperphosphorylated, which promotes complex formation with 14-3-3 adapter protein and decreases interaction with the CCR4-NOT deadenylase subunit Caf1a. Knockdown of Zfp36l1 increased basal Mkp-1 mRNA levels by prolonging its half-life, and this elevated MKP-1 inhibited p38 MAPK activation during LPS stimulation, consequently downregulating TNFα and TTP expression.\",\n      \"method\": \"siRNA knockdown, mRNA half-life assay, co-immunoprecipitation (14-3-3 and Caf1a), phosphorylation analysis\",\n      \"journal\": \"Journal of inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — siRNA knockdown with mRNA half-life, co-IP of 14-3-3 and Caf1a interactions, single lab\",\n      \"pmids\": [\"26180518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZFP36L1 and ZFP36L2 are critical for maintaining quiescence in developing B lymphocytes before pre-BCR expression and for reestablishing quiescence after pre-BCR-induced expansion. These proteins suppress a posttranscriptional regulon of mRNAs whose protein products cooperatively promote S-phase entry, thus promoting VDJ recombination and selection of cells expressing immunoglobulin-μ at the pre-BCR checkpoint.\",\n      \"method\": \"Conditional knockout mice (Zfp36l1/l2 double KO in B cells), RNA-seq, BrdU incorporation cell-cycle analysis, V(D)J recombination assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional double KO in vivo with defined molecular phenotype (cell cycle regulon), replicated across multiple functional assays\",\n      \"pmids\": [\"27102483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZFP36L1 is an FXR target gene that post-transcriptionally regulates bile acid metabolism by destabilizing Cyp7a1 mRNA. Gain-of-function and loss-of-function of ZFP36L1 reciprocally regulated Cyp7a1 mRNA and bile acid levels in vivo. Mice with hepatic ZFP36L1 deletion were protected from diet-induced obesity and hepatosteatosis due to impaired lipid absorption linked to altered bile acid metabolism.\",\n      \"method\": \"Conditional hepatic Zfp36l1 KO mice, adeno-associated virus overexpression, Cyp7a1 mRNA half-life assay, bile acid quantification, diet-induced obesity model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic gain- and loss-of-function with defined molecular (Cyp7a1 mRNA) and physiological (bile acids, obesity) phenotypes\",\n      \"pmids\": [\"28891815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZFP36L1 and ZFP36L2 inhibit cell proliferation and arrest the cell cycle at G1 phase in a cyclin D-dependent and p53-independent manner. Forced expression of ZFP36L1 inhibited cyclin D expression and cell proliferation in p53-null and p53-mutant colorectal cancer cell lines. Zinc-finger domain mutation abolished these antiproliferative effects, confirming that RNA-binding activity through the tandem zinc-finger domain is required.\",\n      \"method\": \"Inducible overexpression, siRNA knockdown, cell cycle analysis (flow cytometry), cyclin D mRNA/protein measurements, zinc-finger domain mutagenesis in three cell lines including p53 KO\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — overexpression and KD with mutagenesis in multiple cell lines, single lab\",\n      \"pmids\": [\"29426877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZFP36L1 directly regulates OA pathogenesis in chondrocytes by destabilizing mRNAs of two HSP70 family members (HSPA1A and related members). ZFP36L1 is specifically upregulated in OA chondrocytes. Genetic ablation or silencing of Zfp36l1 abrogated experimental OA in mice, and this was associated with increased HSP70 expression. Overexpression of HSPA1A in joint tissue protected against OA by inhibiting chondrocyte apoptosis.\",\n      \"method\": \"Adenovirus-mediated overexpression/knockdown, genetic KO mouse OA model (intraarticular injection), identification of HSP70 as direct mRNA targets, HSPA1A overexpression rescue experiment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic KO and OE models plus identification of direct mRNA targets plus rescue experiment\",\n      \"pmids\": [\"30622281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZFP36L1 functions as a tumor suppressor by binding to ARE sequences in the 3'-UTRs of HIF1A, CCND1, and E2F1 mRNAs for degradation, suppressing hypoxic signaling and cell-cycle progression. Wild-type but not zinc-finger-mutant ZFP36L1 bound HIF1A 3'-UTR in dual luciferase reporter assays and RNA-EMSA, mediating HIF1A mRNA degradation. Systematic RNA pull-down with WT vs. mutant ZFP36L1 and whole-transcriptome sequencing identified 1,410 potential direct targets.\",\n      \"method\": \"RNA pull-down with WT vs. zinc-finger mutant ZFP36L1, transcriptome sequencing, dual luciferase reporter assay, RNA-EMSA, forced expression and silencing in bladder cancer cells in vitro and in vivo\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic RNA pull-down plus EMSA plus reporter assay with mutagenesis, functional in vivo xenograft validation\",\n      \"pmids\": [\"31551365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-93-3p promotes keratinocyte proliferation and migration during skin wound healing by directly targeting ZFP36L1, reducing its expression. ZFP36L1 silencing mirrored miR-93-3p overexpression effects on proliferation and migration. ZFP36L1 in turn targets ZFX mRNA for degradation; ZFX overexpression promoted proliferation and migration, placing ZFP36L1 upstream of ZFX in keratinocyte wound-healing signaling.\",\n      \"method\": \"In vivo mouse wound model, miRNA overexpression/inhibition, siRNA knockdown, luciferase 3'UTR reporter assay for miR-93-3p→ZFP36L1 and ZFP36L1→ZFX interactions\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — in vivo model plus reporter validation of two regulatory steps, single lab\",\n      \"pmids\": [\"33473330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZFP36L1 facilitates antibody-secreting cell (ASC) homing to the bone marrow by directly regulating the mRNA abundance of G protein-coupled receptor kinase 2 (GRK2) and the integrin chains α4 and β1. Loss of ZFP36L1 caused ASC accumulation in spleen and liver with reduced bone marrow homing. Differential effects on early vs. late ASCs correlated with the expression of CXCR4 and integrins α4/β1 regulated by ZFP36L1.\",\n      \"method\": \"Zfp36l1 conditional KO mice, flow cytometry of ASC localization, identification of GRK2/integrin α4/β1 as direct ZFP36L1 mRNA targets, CXCR4 expression analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO in vivo with mechanistic identification of direct mRNA targets linking migration phenotype to molecular mechanism\",\n      \"pmids\": [\"33306108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZFP36L1 controls small cell lung cancer (SCLC) neuroendocrine plasticity by binding and destabilizing SOX2 and INSM1 mRNAs, two transcription factors required for SCLC neuroendocrine differentiation. LSD1 binds and represses ZFP36L1; upon LSD1 inhibition, ZFP36L1 expression is restored, blocking the neuroendocrine phenotype and inducing a non-neuroendocrine inflammatory phenotype. ZFP36L1 was identified as required for LSD1 inhibitor sensitivity in a genome-wide CRISPR/Cas9 screen.\",\n      \"method\": \"Genome-wide CRISPR/Cas9 loss-of-function screen, ZFP36L1 forced expression, RNA-IP demonstrating ZFP36L1 binding to SOX2/INSM1 mRNAs, mRNA stability assays, LSD1 ChIP\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide CRISPR screen plus direct RNA binding (RIP) plus mRNA stability plus ChIP for upstream regulator, multiple orthogonal methods\",\n      \"pmids\": [\"36008402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The cMG1 gene (later identified as ZFP36L1) is a primary response gene induced 2- to 6-fold by mitogens including EGF, angiotensin II, serum, and insulin in a rat intestinal epithelial cell line. Cyclic AMP-elevating agents blocked EGF-induced cMG1 mRNA increase, and depletion of protein kinase C blocked AII- but not EGF-induced increases, indicating that both PKC-dependent and PKC-independent signaling pathways stimulate ZFP36L1 expression.\",\n      \"method\": \"Northern blot mRNA quantification, PKC depletion, cAMP signaling inhibition, differential mitogen stimulation\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — mRNA expression measurements only, no mechanistic protein-level functional data\",\n      \"pmids\": [\"1628738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Berg36 (ZFP36L1) immediate early gene expression is induced by calcium ionophore in Ramos human B cells, and antisense blockade of Berg36 expression partially inhibited ionophore-induced apoptosis, implicating ZFP36L1 as a requirement for apoptosis induced through calcium signaling in B cells. IL-4 rescue from apoptosis was accompanied by inhibition of Berg36 expression.\",\n      \"method\": \"Antisense oligonucleotide knockdown, apoptosis assays, IL-4 and calcium ionophore treatment of Ramos B cells\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — antisense KD with apoptosis phenotype, no molecular mechanism identified, single lab\",\n      \"pmids\": [\"8898945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The TIS11 family members (ZFP36, ZFP36L1/BRF-1, ZFP36L2/BRF-2) bind ARE-containing mRNAs and promote their rapid degradation through multiple mechanisms: they recruit deadenylases (CCR4-NOT, PARN), decapping enzymes (DCP1/2), and exonucleases (XRN1, exosome), and their activity is regulated by phosphorylation (MK2, PKB), protein stability (proteasomal degradation), 14-3-3 binding, and subcellular localization.\",\n      \"method\": \"Review synthesizing co-IP, in vitro decay, phosphorylation, and localization studies from multiple labs\",\n      \"journal\": \"Wiley interdisciplinary reviews. RNA\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — synthesis of replicated findings across multiple labs; mechanistic details independently validated\",\n      \"pmids\": [\"21278925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZFP36L1 and ZFP36L2 act redundantly in myogenesis. Mice with conditional double KO of Zfp36l1 and Zfp36l2 in Pax7-expressing satellite cells had reduced body weight, reduced skeletal muscle mass, fewer satellite cells, and impaired muscle regeneration following cardiotoxin injury. Single KO of either gene alone did not produce the muscle phenotype, demonstrating functional redundancy.\",\n      \"method\": \"Single and double conditional KO mice (Pax7-Cre), immunostaining of muscle sections, cardiotoxin injury regeneration model, satellite cell quantification\",\n      \"journal\": \"Skeletal muscle\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic double KO with clear muscle phenotype and redundancy demonstrated through single vs. double KO comparison\",\n      \"pmids\": [\"30526691\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZFP36L1 is a tandem CCCH zinc-finger RNA-binding protein that binds AU-rich elements (AREs) in the 3'-UTRs of target mRNAs (including VEGF, HIF1A, CCND1, BCL2, Cyp7a1, Nanog, Stat5b, SOX2, INSM1, GRK2, and integrin α4/β1 mRNAs) and promotes their deadenylation and degradation by recruiting the CCR4-NOT deadenylase complex and other mRNA decay enzymes; its destabilizing activity is reversibly inactivated by PKB/Akt- and MK2-mediated phosphorylation at S92 and S203, which induces 14-3-3 binding and sequesters the protein from the decay machinery, while RSK (downstream of ERK) phosphorylation of its C-terminus dissociates the CCR4-NOT complex; through these mechanisms ZFP36L1 controls cell quiescence in lymphocytes, erythroid differentiation, bile acid metabolism, neuroendocrine plasticity, muscle satellite cell maintenance, and antibody-secreting cell homing.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ZFP36L1 is an ARE-binding protein of the tristetraprolin family that uses tandem CCCH zinc finger domains to bind AU-rich elements in target mRNA 3′-UTRs and recruit the CCR4-NOT deadenylase complex, thereby accelerating mRNA deadenylation and decay [PMID:12198173, PMID:25106868]. Its destabilizing activity is negatively regulated by phosphorylation at serine 92 by PKB/Akt or at C-terminal sites by RSK, which promotes 14-3-3 binding and dissociation from the deadenylase complex, stabilizing target transcripts [PMID:15538381, PMID:25106868]. Through this mechanism ZFP36L1 controls the turnover of a broad set of mRNAs—including VEGF, HIF1A, CCND1, Nanog, BCL2, SOX2, Stat5b, Cyp7a1, and LDLR—thereby influencing angiogenesis, pluripotency, bile acid metabolism, erythropoiesis, and tumor cell proliferation [PMID:15467755, PMID:24733888, PMID:28891815, PMID:31551365]. In developing lymphocytes, ZFP36L1 (together with ZFP36L2) enforces quiescence by suppressing a regulon of cell-cycle-promoting mRNAs, enabling V(D)J recombination and proper B-cell development [PMID:27102483].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Early antisense experiments implicated ZFP36L1 (Berg36) as a pro-apoptotic factor in B cells, raising the question of whether it directly controls gene expression to affect cell fate.\",\n      \"evidence\": \"Antisense blockade in Ramos B cells partially inhibited ionophore-induced apoptosis\",\n      \"pmids\": [\"8898945\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Antisense approach alone, no direct target mRNAs identified\", \"No reciprocal gain-of-function\", \"Mechanism of apoptosis promotion unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Functional cloning established ZFP36L1 as a bona fide ARE-mRNA decay factor whose CCCH zinc fingers are essential for binding and destabilizing AU-rich element–containing transcripts, resolving its molecular activity.\",\n      \"evidence\": \"Retroviral rescue screen, siRNA knockdown, zinc-finger mutant transfection with ARE-reporter assay in mammalian cells\",\n      \"pmids\": [\"12198173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous mRNA targets not yet identified\", \"Mechanism of decay (deadenylation vs. decapping) unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of VEGF and StAR as direct endogenous targets, and the demonstration that PKB/Akt phosphorylation at S92 induces 14-3-3 binding to inactivate ZFP36L1, established both a physiological target repertoire and a signal-responsive regulatory switch.\",\n      \"evidence\": \"In vitro mRNA decay reconstitution, S92 mutagenesis, RNP-IP of VEGF mRNA, StAR 3′-UTR binding assays, 14-3-3 co-IP\",\n      \"pmids\": [\"15538381\", \"15467755\", \"19179481\", \"14976220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether phosphorylation affects nuclear–cytoplasmic distribution unclear\", \"Full phosphosite map not determined\", \"Antagonism with HuR demonstrated but mechanistic basis unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Extension of the target repertoire to Stat5b mRNA in erythroid differentiation and multiple angiogenic/inflammatory cytokine mRNAs demonstrated that ZFP36L1 functions as a broad posttranscriptional repressor across hematopoietic and vascular contexts.\",\n      \"evidence\": \"Overexpression and siRNA in CD34+ cells with erythroid colony assays; protein transduction of ZFP36L1 into tumor cells and intratumoral injection in mouse xenografts\",\n      \"pmids\": [\"20702587\", \"20802528\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of ZFP36L1 vs. paralogues (TTP, ZFP36L2) to each target unclear\", \"In vivo erythroid phenotype from knockout not yet shown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that ZFP36L1 recruits the CCR4-NOT deadenylase complex and that RSK-mediated phosphorylation dissociates this complex provided the molecular mechanism of decay promotion and its signal-dependent inactivation, while new targets (LDLR, BCL2, Nanog) expanded the functional scope to cholesterol homeostasis, apoptosis resistance, and pluripotency.\",\n      \"evidence\": \"Proteomic RNA pull-down identifying CCR4-NOT, in vitro RSK phosphorylation, epistasis with ERK inhibitors in ESCs, RNA EMSA for BCL2 ARE binding\",\n      \"pmids\": [\"25106868\", \"24733888\", \"25014217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CCR4-NOT recruitment not resolved\", \"Whether RSK and PKB/Akt phospho-sites are functionally redundant or additive unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstration that ZFP36L1 phosphorylation during LPS signaling shifts its interaction from Caf1a deadenylase toward 14-3-3, stabilizing MKP-1 mRNA and attenuating p38 MAPK, integrated ZFP36L1 into innate immune signal termination.\",\n      \"evidence\": \"siRNA, mRNA half-life measurement, 14-3-3 and Caf1a co-immunoprecipitation in macrophage-like cells\",\n      \"pmids\": [\"26180518\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only single Co-IP direction shown for Caf1a interaction\", \"In vivo innate immune phenotype of ZFP36L1 loss not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Conditional knockout in the B-cell lineage revealed that ZFP36L1 (with ZFP36L2) enforces quiescence by suppressing a posttranscriptional regulon of S-phase-promoting mRNAs, establishing its essential developmental role in enabling V(D)J recombination.\",\n      \"evidence\": \"Conditional double knockout mice, cell cycle analysis, RNA target identification in developing B cells\",\n      \"pmids\": [\"27102483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contributions of ZFP36L1 vs. ZFP36L2 to quiescence not separated\", \"Identity of all regulon members not fully catalogued\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Liver-specific gain- and loss-of-function demonstrated that ZFP36L1, as an FXR target gene, mediates rapid posttranscriptional degradation of Cyp7a1 mRNA, linking it to bile acid homeostasis in vivo.\",\n      \"evidence\": \"Conditional liver-specific knockout and overexpression mice, bile acid measurements, mRNA stability assay\",\n      \"pmids\": [\"28891815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ZFP36L1 controls other bile acid pathway mRNAs not determined\", \"Mechanism of FXR-induced ZFP36L1 transcription not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"TZF domain mutagenesis confirmed that the antiproliferative function of ZFP36L1 depends on its RNA-binding capacity and operates through cyclin D suppression independently of p53, while double knockout in satellite cells revealed a role in muscle stem cell maintenance.\",\n      \"evidence\": \"Overexpression/mutagenesis in p53-null cell lines; Pax7-Cre conditional double knockout mice with muscle injury model\",\n      \"pmids\": [\"29426877\", \"30526691\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding of ZFP36L1 to cyclin D1 mRNA vs. indirect effect not distinguished in mutagenesis study\", \"Satellite cell targets of ZFP36L1 not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of HIF1A, CCND1, and HSP70 family mRNAs as direct ZFP36L1 targets extended its role to hypoxia signaling suppression in cancer and cartilage homeostasis, with in vivo knockout in chondrocytes protecting against osteoarthritis.\",\n      \"evidence\": \"RNA pull-down with WT/mutant ZFP36L1, transcriptome sequencing, Zfp36l1 knockout mice in OA model\",\n      \"pmids\": [\"31551365\", \"30622281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ZFP36L1 loss in cancer is a driver or passenger event not established\", \"Structural basis for target selectivity among AREs unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Conditional deletion in B-lineage plasma cells showed ZFP36L1 controls antibody-secreting cell homing by destabilizing GRK2 and integrin mRNAs, revealing a non-redundant immune function distinct from its earlier-characterized role in B-cell quiescence.\",\n      \"evidence\": \"Conditional gene deletion, in vivo ASC homing assay, RNA-binding confirmation\",\n      \"pmids\": [\"33306108\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ZFP36L2 compensates partially in ASCs not tested\", \"Full target repertoire in ASCs not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A genome-wide CRISPR screen identified ZFP36L1 as the effector of LSD1 inhibitor–induced neuroendocrine-to-inflammatory phenotype switching in SCLC, mediated by destabilization of SOX2 and INSM1 mRNAs, connecting epigenetic derepression of ZFP36L1 to tumor cell fate plasticity.\",\n      \"evidence\": \"CRISPR/Cas9 screen in SCLC lines, mRNA decay and RNA-binding assays, LSD1 ChIP, phenotypic rescue\",\n      \"pmids\": [\"36008402\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ZFP36L1 is sufficient for phenotype switching without LSD1 inhibition unknown\", \"In vivo tumor model validation not performed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for ZFP36L1's recruitment of CCR4-NOT and its selectivity among ARE-containing mRNAs, the degree of functional redundancy with TTP and ZFP36L2 across tissues, and whether phosphorylation by different kinases (PKB, RSK) produces qualitatively distinct outcomes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of ZFP36L1–CCR4-NOT complex\", \"Systematic transcriptome-wide identification of direct targets across tissues incomplete\", \"Kinase-specific phospho-codes and their functional consequences not delineated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 1, 2, 3, 8, 13, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 8, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 8, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0008953854\", \"supporting_discovery_ids\": [0, 3, 8, 13]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 3, 8, 13]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 8, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 17]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [10, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CNOT1\", \"14-3-3\", \"ELAVL1\", \"ZFP36L2\"],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I made an error in the pathway section. Let me fix the duplicate/incorrect entry `GO:0008953854`. The correct Reactome term is `R-HSA-8953854`. Let me also reconsider the localization — the cytosol localization is inferred from the functional context (mRNA decay in cytoplasm, 14-3-3 binding), but let me check if any discovery explicitly states localization. The discoveries mention cytoplasmic mRNA decay activity but don't explicitly characterize localization. I'll keep cytosol since the in vitro reconstitution and functional data strongly imply cytoplasmic/cytosolic activity.\n\n```json\n{\n  \"mechanistic_narrative\": \"ZFP36L1 is an ARE-binding protein of the tristetraprolin family that uses tandem CCCH zinc finger domains to bind AU-rich elements in target mRNA 3′-UTRs and recruit the CCR4-NOT deadenylase complex, thereby accelerating mRNA deadenylation and decay [PMID:12198173, PMID:25106868]. Its destabilizing activity is negatively regulated by phosphorylation at serine 92 by PKB/Akt or at C-terminal sites by RSK, which promotes 14-3-3 binding and dissociation from the deadenylase complex, stabilizing target transcripts [PMID:15538381, PMID:25106868]. Through this mechanism ZFP36L1 controls the turnover of a broad set of mRNAs—including VEGF, HIF1A, CCND1, Nanog, BCL2, SOX2, Stat5b, Cyp7a1, and LDLR—thereby influencing angiogenesis, pluripotency, bile acid metabolism, erythropoiesis, and tumor cell proliferation [PMID:15467755, PMID:24733888, PMID:28891815, PMID:31551365]. In developing lymphocytes, ZFP36L1 (together with ZFP36L2) enforces quiescence by suppressing a regulon of cell-cycle-promoting mRNAs, enabling V(D)J recombination and proper B-cell development [PMID:27102483].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Early antisense experiments implicated ZFP36L1 (Berg36) as a pro-apoptotic factor in B cells, raising the question of whether it directly controls gene expression to affect cell fate.\",\n      \"evidence\": \"Antisense blockade in Ramos B cells partially inhibited ionophore-induced apoptosis\",\n      \"pmids\": [\"8898945\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Antisense approach alone, no direct target mRNAs identified\", \"No reciprocal gain-of-function\", \"Mechanism of apoptosis promotion unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Functional cloning established ZFP36L1 as a bona fide ARE-mRNA decay factor whose CCCH zinc fingers are essential for binding and destabilizing AU-rich element–containing transcripts, resolving its molecular activity.\",\n      \"evidence\": \"Retroviral rescue screen, siRNA knockdown, zinc-finger mutant transfection with ARE-reporter assay in mammalian cells\",\n      \"pmids\": [\"12198173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous mRNA targets not yet identified\", \"Mechanism of decay (deadenylation vs. decapping) unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of VEGF and StAR as direct endogenous targets, and the demonstration that PKB/Akt phosphorylation at S92 induces 14-3-3 binding to inactivate ZFP36L1, established both a physiological target repertoire and a signal-responsive regulatory switch.\",\n      \"evidence\": \"In vitro mRNA decay reconstitution, S92 mutagenesis, RNP-IP of VEGF mRNA, StAR 3′-UTR binding assays, 14-3-3 co-IP\",\n      \"pmids\": [\"15538381\", \"15467755\", \"19179481\", \"14976220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether phosphorylation affects nuclear-cytoplasmic distribution unclear\", \"Full phosphosite map not determined\", \"Antagonism with HuR demonstrated but mechanistic basis unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Extension of the target repertoire to Stat5b mRNA in erythroid differentiation and multiple angiogenic/inflammatory cytokine mRNAs demonstrated that ZFP36L1 functions as a broad posttranscriptional repressor across hematopoietic and vascular contexts.\",\n      \"evidence\": \"Overexpression and siRNA in CD34+ cells with erythroid colony assays; protein transduction of ZFP36L1 into tumor cells and intratumoral injection in mouse xenografts\",\n      \"pmids\": [\"20702587\", \"20802528\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of ZFP36L1 vs. paralogues (TTP, ZFP36L2) to each target unclear\", \"In vivo erythroid phenotype from knockout not yet shown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that ZFP36L1 recruits the CCR4-NOT deadenylase complex and that RSK-mediated phosphorylation dissociates this complex provided the molecular mechanism of decay promotion and its signal-dependent inactivation, while new targets (LDLR, BCL2, Nanog) expanded the functional scope to cholesterol homeostasis, apoptosis resistance, and pluripotency.\",\n      \"evidence\": \"Proteomic RNA pull-down identifying CCR4-NOT, in vitro RSK phosphorylation, epistasis with ERK inhibitors in ESCs, RNA EMSA for BCL2 ARE binding\",\n      \"pmids\": [\"25106868\", \"24733888\", \"25014217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CCR4-NOT recruitment not resolved\", \"Whether RSK and PKB/Akt phospho-sites are functionally redundant or additive unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstration that ZFP36L1 phosphorylation during LPS signaling shifts its interaction from Caf1a deadenylase toward 14-3-3, stabilizing MKP-1 mRNA and attenuating p38 MAPK, integrated ZFP36L1 into innate immune signal termination.\",\n      \"evidence\": \"siRNA, mRNA half-life measurement, 14-3-3 and Caf1a co-immunoprecipitation in macrophage-like cells\",\n      \"pmids\": [\"26180518\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only single Co-IP direction shown for Caf1a interaction\", \"In vivo innate immune phenotype of ZFP36L1 loss not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Conditional knockout in the B-cell lineage revealed that ZFP36L1 (with ZFP36L2) enforces quiescence by suppressing a posttranscriptional regulon of S-phase-promoting mRNAs, establishing its essential developmental role in enabling V(D)J recombination.\",\n      \"evidence\": \"Conditional double knockout mice, cell cycle analysis, RNA target identification in developing B cells\",\n      \"pmids\": [\"27102483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contributions of ZFP36L1 vs. ZFP36L2 to quiescence not separated\", \"Identity of all regulon members not fully catalogued\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Liver-specific gain- and loss-of-function demonstrated that ZFP36L1, as an FXR target gene, mediates rapid posttranscriptional degradation of Cyp7a1 mRNA, linking it to bile acid homeostasis in vivo.\",\n      \"evidence\": \"Conditional liver-specific knockout and overexpression mice, bile acid measurements, mRNA stability assay\",\n      \"pmids\": [\"28891815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ZFP36L1 controls other bile acid pathway mRNAs not determined\", \"Mechanism of FXR-induced ZFP36L1 transcription not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"TZF domain mutagenesis confirmed that the antiproliferative function of ZFP36L1 depends on its RNA-binding capacity and operates through cyclin D suppression independently of p53, while double knockout in satellite cells revealed a role in muscle stem cell maintenance.\",\n      \"evidence\": \"Overexpression/mutagenesis in p53-null cell lines; Pax7-Cre conditional double knockout mice with muscle injury model\",\n      \"pmids\": [\"29426877\", \"30526691\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding of ZFP36L1 to cyclin D1 mRNA vs. indirect effect not distinguished in mutagenesis study\", \"Satellite cell targets of ZFP36L1 not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of HIF1A, CCND1, and HSP70 family mRNAs as direct ZFP36L1 targets extended its role to hypoxia signaling suppression in cancer and cartilage homeostasis, with in vivo knockout in chondrocytes protecting against osteoarthritis.\",\n      \"evidence\": \"RNA pull-down with WT/mutant ZFP36L1, transcriptome sequencing, Zfp36l1 knockout mice in OA model\",\n      \"pmids\": [\"31551365\", \"30622281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ZFP36L1 loss in cancer is a driver or passenger event not established\", \"Structural basis for target selectivity among AREs unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Conditional deletion in B-lineage plasma cells showed ZFP36L1 controls antibody-secreting cell homing by destabilizing GRK2 and integrin mRNAs, revealing a non-redundant immune function distinct from its earlier-characterized role in B-cell quiescence.\",\n      \"evidence\": \"Conditional gene deletion, in vivo ASC homing assay, RNA-binding confirmation\",\n      \"pmids\": [\"33306108\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ZFP36L2 compensates partially in ASCs not tested\", \"Full target repertoire in ASCs not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A genome-wide CRISPR screen identified ZFP36L1 as the effector of LSD1 inhibitor–induced neuroendocrine-to-inflammatory phenotype switching in SCLC, mediated by destabilization of SOX2 and INSM1 mRNAs, connecting epigenetic derepression of ZFP36L1 to tumor cell fate plasticity.\",\n      \"evidence\": \"CRISPR/Cas9 screen in SCLC lines, mRNA decay and RNA-binding assays, LSD1 ChIP, phenotypic rescue\",\n      \"pmids\": [\"36008402\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ZFP36L1 is sufficient for phenotype switching without LSD1 inhibition unknown\", \"In vivo tumor model validation not performed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for ZFP36L1's recruitment of CCR4-NOT and its selectivity among ARE-containing mRNAs, the degree of functional redundancy with TTP and ZFP36L2 across tissues, and whether phosphorylation by different kinases (PKB, RSK) produces qualitatively distinct outcomes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of ZFP36L1-CCR4-NOT complex\", \"Systematic transcriptome-wide identification of direct targets across tissues incomplete\", \"Kinase-specific phospho-codes and their functional consequences not delineated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 1, 2, 3, 8, 13, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 8, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 3, 8, 13]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 8, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 17]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [10, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CNOT1\", \"YWHAZ\", \"ZFP36L2\", \"ELAVL1\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ZFP36L1 is a tandem CCCH zinc-finger RNA-binding protein that recognizes AU-rich elements (AREs) in the 3′-UTRs of target mRNAs and promotes their deadenylation and degradation by recruiting the CCR4-NOT deadenylase complex, decapping enzymes, and exonucleases, thereby delivering ARE-containing transcripts to processing bodies [PMID:12198173, PMID:15687258, PMID:25106868, PMID:17369404]. Its mRNA-destabilizing activity is reversibly inactivated by PKB/Akt phosphorylation at S92 and S203, which induces 14-3-3 binding and protects ZFP36L1 from proteasomal degradation, and by MK2 phosphorylation, while RSK-mediated phosphorylation dissociates the CCR4-NOT complex to stabilize target mRNAs [PMID:17030608, PMID:18326031, PMID:25106868]. Through post-transcriptional control of functionally diverse ARE-containing mRNAs—including VEGF, HIF1A, CCND1, Nanog, Cyp7a1, SOX2, INSM1, Stat5b, GRK2, and BCL2—ZFP36L1 regulates lymphocyte quiescence, erythroid differentiation, bile acid metabolism, neuroendocrine cell plasticity, satellite cell maintenance, and antibody-secreting cell homing [PMID:27102483, PMID:20702587, PMID:28891815, PMID:36008402, PMID:30526691, PMID:33306108]. Conditional knockout studies demonstrate that ZFP36L1 acts redundantly with ZFP36L2 in B-cell quiescence and muscle satellite cell biology, while uniquely controlling hepatic Cyp7a1 mRNA turnover to regulate bile acid homeostasis and protect against diet-induced obesity [PMID:27102483, PMID:30526691, PMID:28891815].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Initial characterization established ZFP36L1 as an immediate-early gene induced by mitogens and calcium signaling, but its molecular function was unknown.\",\n      \"evidence\": \"Northern blot in mitogen-stimulated epithelial cells and antisense knockdown in B cells showing partial apoptosis inhibition\",\n      \"pmids\": [\"1628738\", \"8898945\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No molecular function identified beyond expression induction\", \"Antisense knockdown apoptosis result not independently confirmed\", \"No direct target mRNAs identified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"A genetic rescue screen established ZFP36L1 as an essential ARE-mRNA decay factor, resolving its molecular function as an RNA-binding protein that accelerates mRNA turnover through its zinc-finger domains.\",\n      \"evidence\": \"Retroviral cDNA rescue of ARE-decay-deficient slowC cells carrying biallelic ZFP36L1 frameshift mutations, validated by siRNA and zinc-finger mutagenesis\",\n      \"pmids\": [\"12198173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of decay enzyme recruitment unknown\", \"Identity of endogenous mRNA targets unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The mechanism by which ZFP36L1 couples ARE recognition to mRNA destruction was elucidated: it contains activation domains that recruit deadenylases, decapping enzymes, and exonucleases, and its first physiological target—VEGF mRNA—was identified.\",\n      \"evidence\": \"Co-IP of decay enzymes with ZFP36L1, tethered decay assays, RNP-IP confirming VEGF mRNA binding, and half-life measurements in primary adrenocortical cells\",\n      \"pmids\": [\"15687258\", \"15467755\", \"14976220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for decay enzyme recruitment unknown\", \"Full repertoire of endogenous targets not defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Discovery that PKB/Akt phosphorylates ZFP36L1 at S92 to inhibit its decay activity without blocking ARE binding revealed the first signaling mechanism controlling this protein, with 14-3-3 sequestration as the inactivation mode.\",\n      \"evidence\": \"In vitro kinase assay, reconstituted decay assay with phospho-mimetic mutants, co-IP with 14-3-3\",\n      \"pmids\": [\"15538381\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of additional phosphosites unknown\", \"In vivo relevance of PKB regulation not tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The phosphoregulation model was refined: cooperative PKB phosphorylation at both S92 and S203 is required for 14-3-3 binding and ZFP36L1 protein stabilization, revealing that ZFP36L1 is a labile protein whose abundance and activity are co-regulated by the same phosphorylation events.\",\n      \"evidence\": \"Double S92A/S203A mutagenesis, proteasome inhibitor rescue, PKBα knockout cells\",\n      \"pmids\": [\"17030608\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin ligase responsible for ZFP36L1 degradation not identified\", \"Relationship between protein turnover and functional output in vivo unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"ZFP36L1 was shown to deliver ARE-mRNAs to processing bodies for degradation, establishing its role in subcellular compartmentalization of mRNA decay.\",\n      \"evidence\": \"siRNA depletion, fluorescent mRNA tracking, and tethering assays in human cells\",\n      \"pmids\": [\"17369404\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether P-body localization is required for or merely accompanies decay not resolved\", \"Relative contribution of cytoplasmic vs. P-body decay unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"MK2 was identified as a second kinase inactivating ZFP36L1 at overlapping sites (S54, S92, S203), acting downstream of p38 MAPK stress signaling and inhibiting decay at a step beyond RNA binding and enzyme recruitment.\",\n      \"evidence\": \"In vitro kinase assays with ZFP36L1 fragments, active MK2 co-expression, ARE-decay functional assays\",\n      \"pmids\": [\"18326031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact post-recruitment step blocked by MK2 phosphorylation unknown\", \"Relative physiological importance of MK2 vs. PKB phosphorylation undefined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The CCR4-NOT deadenylase complex was identified as the specific effector recruited by ZFP36L1's C-terminus, and RSK (downstream of ERK) was shown to phosphorylate this region to dissociate CCR4-NOT and stabilize target mRNAs such as LDLR, completing the picture of three kinase inputs converging on ZFP36L1.\",\n      \"evidence\": \"Proteomic 3′-UTR pull-down, CCR4-NOT co-IP, in vitro RSK phosphorylation, antisense oligonucleotide validation\",\n      \"pmids\": [\"25106868\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CCR4-NOT interaction and its phosphorylation-dependent dissociation not resolved\", \"Relative contribution of deadenylation vs. other decay routes for individual targets unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"ZFP36L1's target repertoire was expanded to include Nanog mRNA in embryonic stem cells, positioning it as an effector of FGF/ERK signaling that attenuates pluripotency and biases mesendoderm differentiation.\",\n      \"evidence\": \"Conditional overexpression in mESCs, Nanog mRNA half-life measurement, ERK pathway epistasis\",\n      \"pmids\": [\"24733888\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Full ZFP36L1 target set in ESCs not defined\", \"In vivo embryonic phenotype of Zfp36l1 loss not reported in this context\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Conditional double knockout of Zfp36l1 and Zfp36l2 in B cells revealed that these proteins enforce quiescence during lymphocyte development by suppressing a post-transcriptional regulon of cell-cycle-promoting mRNAs, establishing a physiological role in adaptive immunity.\",\n      \"evidence\": \"Conditional double KO mice, RNA-seq, BrdU cell-cycle analysis, V(D)J recombination assays\",\n      \"pmids\": [\"27102483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contributions of ZFP36L1 vs. ZFP36L2 to the quiescence regulon not separated\", \"Identity of critical individual target mRNAs within the regulon not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"ZFP36L1 was established as a metabolic regulator downstream of FXR: it destabilizes Cyp7a1 mRNA to control bile acid synthesis, and hepatic deletion protects against diet-induced obesity, linking mRNA decay to systemic metabolic homeostasis.\",\n      \"evidence\": \"Conditional hepatic Zfp36l1 KO, AAV overexpression, Cyp7a1 mRNA half-life, bile acid quantification, diet-induced obesity model\",\n      \"pmids\": [\"28891815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional hepatic ZFP36L1 targets contribute to the metabolic phenotype not defined\", \"Human relevance of the Cyp7a1-bile acid axis regulation by ZFP36L1 not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Functional redundancy between ZFP36L1 and ZFP36L2 was demonstrated in muscle satellite cells, where double but not single knockout caused satellite cell depletion and impaired regeneration, extending the quiescence-enforcement paradigm beyond lymphocytes to stem cell biology.\",\n      \"evidence\": \"Single and double conditional KO in Pax7+ satellite cells, cardiotoxin injury regeneration model\",\n      \"pmids\": [\"30526691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mRNA targets in satellite cells not identified\", \"Mechanism of satellite cell loss (exhaustion vs. differentiation vs. death) not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"ZFP36L1's tumor-suppressor function was mechanistically defined through identification of HIF1A, CCND1, and E2F1 as direct targets, linking ARE-mediated decay to suppression of hypoxic signaling and cell-cycle progression, while systematic RNA pull-down identified over 1,400 potential target mRNAs.\",\n      \"evidence\": \"RNA pull-down with WT vs. zinc-finger mutant ZFP36L1, transcriptome-wide sequencing, RNA-EMSA, reporter assays, in vivo xenograft\",\n      \"pmids\": [\"31551365\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fraction of 1,410 candidate targets that are functionally relevant unknown\", \"Whether tumor-suppressor activity is context-dependent across cancer types not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"ZFP36L1 was found to direct antibody-secreting cell trafficking to bone marrow by regulating GRK2 and integrin α4/β1 mRNA levels, revealing a role in immune cell migration distinct from its quiescence function.\",\n      \"evidence\": \"Conditional KO mice, flow cytometry of ASC distribution, identification of GRK2 and integrin mRNAs as direct targets\",\n      \"pmids\": [\"33306108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ZFP36L1 controls homing of other immune cell types unknown\", \"Mechanism discriminating which targets are regulated in ASCs vs. other cell types unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"ZFP36L1 was identified as a master regulator of neuroendocrine plasticity in SCLC: it destabilizes SOX2 and INSM1 mRNAs, and its epigenetic silencing by LSD1 is required for maintenance of the neuroendocrine phenotype, explaining LSD1 inhibitor sensitivity.\",\n      \"evidence\": \"Genome-wide CRISPR screen, RNA-IP for SOX2/INSM1, mRNA stability assays, LSD1 ChIP\",\n      \"pmids\": [\"36008402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ZFP36L1 controls neuroendocrine plasticity in other tumor types unknown\", \"Full set of ZFP36L1 targets mediating phenotypic switching not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for ZFP36L1's selective recruitment of the CCR4-NOT complex and how phosphorylation at distinct sites differentially modulates deadenylase association, P-body delivery, and proteasomal turnover remains unresolved; the rules governing target selectivity among the >1,400 candidate ARE-mRNAs in different cell types are also undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal or cryo-EM structure of ZFP36L1 in complex with CCR4-NOT or ARE RNA\", \"Target selectivity rules across cell types not defined\", \"In vivo contribution of individual phosphorylation sites (S54, S92, S203) not dissected by knock-in\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 2, 3, 14, 15, 21, 24]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 3, 14, 27]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [17, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 3, 6, 14, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 5, 7, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [17, 23]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [17, 19]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [10, 13, 28]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CNOT1\",\n      \"YWHAB\",\n      \"DCP1A\",\n      \"XRN1\",\n      \"PARN\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}